Cyclophilins are a family of enzymes with peptidyl-prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of human diseases. This review describes the structural characteristics of individual cyclophilin isoforms and explores the roles that they play in human health and diseases, such as in viral infections, Alzheimer's disease, Parkinson's disease, cardiovascular diseases, or cancer. Additionally, the review addresses inhibition of cyclophilins, particularly focusing on the development of selective small-molecule inhibitors of individual cyclophilins, which possess a significant potential as novel therapeutics.

Department of Chemistry Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic

University Hospital Hradec Kralove Biomedical Research Centre Hradec Kralove Czech Republic

Zobrazit více v PubMed

Fischer G., Bang H., and Mech C., “[Determination of Enzymatic Catalysis for the Cis‐Trans‐Isomerization of Peptide Binding in Proline‐Containing Peptides],” Biomedica Biochimica Acta 43, no. 10 (1984): 1101–1111. PubMed

Handschumacher R. E., Harding M. W., Rice J., Drugge R. J., and Speicher D. W., “Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A,” Science 226, no. 4674 (1984): 544–547, 10.1126/science.6238408. PubMed DOI

Fischer G., Wittmann‐Liebold B., Lang K., Kiefhaber T., and Schmid F. X., “Cyclophilin and Peptidyl‐Prolyl Cis‐Trans Isomerase Are Probably Identical Proteins,” Nature 337, no. 6206 (1989): 476–478, 10.1038/337476a0. PubMed DOI

Kumari S., Roy S., Singh P., Singla‐Pareek S. L., and Pareek A., “Cyclophilins: Proteins in Search of Function,” Plant Signaling & Behavior 8, no. 1 (2013): 22734, 10.4161/psb.22734. PubMed DOI PMC

Davis T. L., Walker J. R., Campagna‐Slater V., et al., “Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl‐Prolyl Isomerases,” PLoS Biology 8, no. 7 (2010): 1000439, 10.1371/journal.pbio.1000439. PubMed DOI PMC

Ferreira P. A. and Orry A., “From PubMed DOI PMC

Rajiv C. and Davis T., “Structural and Functional Insights Into Human Nuclear Cyclophilins,” Biomolecules 8, no. 4 (2018): 161, 10.3390/biom8040161. PubMed DOI PMC

Spik G., Haendler B., Delmas O., et al., “A Novel Secreted Cyclophilin‐Like Protein (SCYLP),” Journal of Biological Chemistry 266, no. 17 (1991): 10735–10738, 10.1016/S0021-9258(18)99078-2. PubMed DOI

Sherry B., Yarlett N., Strupp A., and Cerami A., “Identification of Cyclophilin as a Proinflammatory Secretory Product of Lipopolysaccharide‐Activated Macrophages,” Proceedings of the National Academy of Sciences 89, no. 8 (1992): 3511–3515, 10.1073/pnas.89.8.3511. PubMed DOI PMC

Suzuki J., Jin Z.‐G., Meoli D. F., Matoba T., and Berk B. C., “Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells,” Circulation Research 98, no. 6 (2006): 811–817, 10.1161/01.RES.0000216405.85080.a6. PubMed DOI

Nigro P., Pompilio G., and Capogrossi M. C., “Cyclophilin A: A Key Player for Human Disease,” Cell Death & Disease 4, no. 10 (2013): e888, 10.1038/cddis.2013.410. PubMed DOI PMC

Gallardo‐Flores C. E. and Colpitts C. C., “Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches,” Pathogens 10, no. 7 (2021): 902, 10.3390/pathogens10070902. PubMed DOI PMC

Edlich F. and Fischer G., “Pharmacological Targeting of Catalyzed Protein Folding: The Example of Peptide Bond Cis/Trans Isomerases.” in Molecular Chaperones in Health and Disease (Vol. 172), eds. Starke K. and Gaestel M.. Handbook of Experimental Pharmacology; Springer‐Verlag, 2006, 359–404, 10.1007/3-540-29717-0_15. PubMed DOI

Galat A., “Peptidylprolyl Cis/Trans Isomerases (Immunophilins): Biological Diversity—Targets—Functions,” Current Topics in Medicinal Chemistry 3, no. 12 (2003): 1315–1347, 10.2174/1568026033451862. PubMed DOI

Stauffer W. T., Goodman A. Z., and Gallay P. A., “Cyclophilin Inhibition as a Strategy for the Treatment of Human Disease,” Frontiers in Pharmacology 15 (2024), 10.3389/fphar.2024.1417945. PubMed DOI PMC

Bukrinsky M., “Extracellular Cyclophilins in Health and Disease,” Biochimica et Biophysica Acta (BBA) ‐ General Subjects 1850, no. 10 (2015): 2087–2095, 10.1016/j.bbagen.2014.11.013. PubMed DOI PMC

Wu Y., Ma Z., Zhang Y., et al., “The Role of Cyclophilins in Viral Infection and the Immune Response,” Journal of Infection 85, no. 4 (2022): 365–373, 10.1016/j.jinf.2022.08.002. PubMed DOI

Arevalo‐Rodriguez M., “Prolyl Isomerases in Yeast,” Frontiers in Bioscience 9, no. 1–3 (2004): 2420, 10.2741/1405. PubMed DOI

The PyMOL Molecular Graphics System, 2.5.2. LLC.

Mark P. and Nilsson L., “A Molecular Dynamics Study of Cyclophilin A Free and in Complex With the Ala‐Pro Dipeptide,” European Biophysics Journal 36, no. 3 (2007): 213–224, 10.1007/s00249-006-0121-3. PubMed DOI

Leone V., Lattanzi G., Molteni C., and Carloni P., “Mechanism of Action of Cyclophilin A Explored by Metadynamics Simulations,” PLoS Computational Biology 5, no. 3 (2009): e1000309, 10.1371/journal.pcbi.1000309. PubMed DOI PMC

Ke H., Mayrose D., Belshaw P. J., et al., “Crystal Structures of Cyclophilin A Complexed With Cyclosporin A and N‐Methyl‐4‐[(E)‐2‐Butenyl]‐4,4‐ Dimethylthreonine Cyclosporin A,” Structure 2, no. 2 (1994): 33–44, 10.1016/S0969-2126(00)00006-X. PubMed DOI

Zhao Y., Chen Y., Schutkowski M., Fischer G., and Ke H., “Cyclophilin A Complexed With a Fragment of HIV‐1 Gag Protein: Insights into HIV‐1 Infectious Activity,” Structure 5 (1997): 139–146, 10.1016/S0969-2126(97)00172-X. PubMed DOI

Howard B. R., Vajdos F. F., Li S., Sundquist W. I., and Hill C. P., “Structural Insights Into the Catalytic Mechanism of Cyclophilin A,” Nature Structural & Molecular Biology 10, no. 6 (2003): 475–481, 10.1038/nsb927. PubMed DOI

Bossard M. J., Koser P. L., Brandt M., Bergsma D. J., and Levy M. A., “A Single Trp121 to Ala121 Mutation in Human Cyclophilin Alters Cyclosporin A Affinity and Peptidyl‐Prolyl Isomerase Activity,” Biochemical and Biophysical Research Communications 176, no. 3 (1991): 1142–1148, 10.1016/0006-291X(91)90404-U. PubMed DOI

Ke H., “Crystal Structures of Cyclophilin and Its Partners,” Frontiers in Bioscience 9 (2004): 2285–2296, 10.2741/1396. PubMed DOI

Stein R. L., “Mechanism of Enzymatic and Nonenzymatic Prolyl Cis‐Trans Isomerization,” Advances in Protein Chemistry 44 (1993): 1–24, 10.1016/S0065-3233(08)60562-8. PubMed DOI

Göthel S. F. and Marahiel M. A., “Peptidyl‐Prolyl Cis‐Trans Isomerases, a Superfamily of Ubiquitous Folding Catalysts,” Cellular and Molecular Life Sciences (CMLS) 55, no. 3 (1999): 423–436, 10.1007/s000180050299. PubMed DOI PMC

Wang P. and Heitman J., “The Cyclophilins,” Genome Biology 6, no. 226 (2005): 0, 10.1186/gb-2005-6-7-226. PubMed DOI PMC

Harrison R. K. and Stein R. L., “Mechanistic Studies of Peptidyl Prolyl Cis‐Trans Isomerase: Evidence for Catalysis by Distortion,” Biochemistry 29, no. 7 (1990): 1684–1689, 10.1021/bi00459a003. PubMed DOI

Kofron J. L., Kuzmic P., Kishore V., Colon‐Bonilla E., and Rich D. H., “Determination of Kinetic Constants for Peptidyl Prolyl Cis‐Trans Isomerases by an Improved Spectrophotometric Assay,” Biochemistry 30, no. 25 (1991): 6127–6134, 10.1021/bi00239a007. PubMed DOI

Armbruster A. M. and Pullman A., “The Effect of Cation Binding on the Rotation Barrier of the Peptide Bond,” FEBS Letters 49, no. 1 (1974): 18–21, 10.1016/0014-5793(74)80621-6. PubMed DOI

Zhao Y. and Ke H., “Crystal Structure Implies That Cyclophilin Predominantly Catalyzes the PubMed DOI

Harikishore A. and Sup Yoon H., “Immunophilins: Structures, Mechanisms and Ligands,” Current Molecular Pharmacology 9, no. 1 (2015): 37–47, 10.2174/1874467208666150519113427. PubMed DOI

Liao Y., Luo D., Peng K., and Zeng Y., “Cyclophilin A: A Key Player for Etiological Agent Infection,” Applied Microbiology and Biotechnology 105, no. 4 (2021): 1365–1377, 10.1007/s00253-021-11115-2. PubMed DOI PMC

Ke H. M., Zydowsky L. D., Liu J., and Walsh C. T., “Crystal Structure of Recombinant Human T‐Cell Cyclophilin A at 2.5 A Resolution,” Proceedings of the National Academy of Sciences 88, no. 21 (1991): 9483–9487, 10.1073/pnas.88.21.9483. PubMed DOI PMC

Sasso J. M., Tenchov R., Wang D., Johnson L. S., Wang X., and Zhou Q. A., “Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic,” Biochemistry 62, no. 3 (2023): 601–623, 10.1021/acs.biochem.2c00245. PubMed DOI PMC

Gamble T. R., Vajdos F. F., Yoo S., et al., “Crystal Structure of Human Cyclophilin A Bound to the Amino‐Terminal Domain of HIV‐1 Capsid,” Cell 87, no. 7 (1996): 1285–1294, 10.1016/S0092-8674(00)81823-1. PubMed DOI

Burse M., Shi J., and Aiken C., “Cyclophilin A Potentiates TRIM5α Inhibition of HIV‐1 Nuclear Import Without Promoting TRIM5α Binding to the Viral Capsid,” PLoS One 12, no. 8 (2017): e0182298, 10.1371/journal.pone.0182298. PubMed DOI PMC

De Iaco A. and Luban J., “Cyclophilin A Promotes HIV‐1 Reverse Transcription but Its Effect on Transduction Correlates Best With Its Effect on Nuclear Entry of Viral CDNA,” Retrovirology 11, no. 1 (2014): 11, 10.1186/1742-4690-11-11. PubMed DOI PMC

Li Y., Kar A. K., and Sodroski J., “Target Cell Type‐Dependent Modulation of Human Immunodeficiency Virus Type 1 Capsid Disassembly by Cyclophilin A,” Journal of Virology 83, no. 21 (2009): 10951–10962, 10.1128/JVI.00682-09. PubMed DOI PMC

Selyutina A., Persaud M., Simons L. M., et al., “Cyclophilin A Prevents HIV‐1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core,” Cell Reports 30 (2020): 3766–3777.e6, 10.1016/j.celrep.2020.02.100. PubMed DOI PMC

Padron A., Dwivedi R., Chakraborty R., et al., “Cyclophilin A Facilitates HIV‐1 Integration,” Journal of Virology 98, no. 11 (2024): e0094724, 10.1128/jvi.00947-24. PubMed DOI PMC

Malfavon‐Borja R., Wu L. I., Emerman M., and Malik H. S., “Birth, Decay, and Reconstruction of an Ancient TRIMCyp Gene Fusion in Primate Genomes,” Proceedings of the National Academy of Sciences 110, no. 7 (2013): 2447, 10.1073/pnas.1216542110. PubMed DOI PMC

Suzuki T., Aizaki H., Murakami K., Shoji I., and Wakita T., “Molecular Biology of Hepatitis C Virus,” Journal of Gastroenterology 42, no. 6 (2007): 411–423, 10.1007/s00535-007-2030-3. PubMed DOI

Watashi K., Hijikata M., Hosaka M., Yamaji M., and Shimotohno K., “Cyclosporin A Suppresses Replication of Hepatitis C Virus Genome in Cultured Hepatocytes,” Hepatology 38, no. 5 (2003): 1282–1288, 10.1053/jhep.2003.50449. PubMed DOI

Nakagawa M., Sakamoto N., Tanabe Y., et al., “Suppression of Hepatitis C Virus Replication by Cyclosporin A Is Mediated by Blockade of Cyclophilins,” Gastroenterology 129, no. 3 (2005): 1031–1041, 10.1053/j.gastro.2005.06.031. PubMed DOI

Chatterji U., Bobardt M., Selvarajah S., et al., “The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication,” Journal of Biological Chemistry 284, no. 25 (2009): 16998–17005, 10.1074/jbc.M109.007625. PubMed DOI PMC

Chatterji U., Bobardt M., Tai A., Wood M., and Gallay P. A., “Cyclophilin and NS5A Inhibitors, but Not Other Anti‐Hepatitis C Virus (HCV) Agents, Preclude HCV‐Mediated Formation of Double‐Membrane‐Vesicle Viral Factories,” Antimicrobial Agents and Chemotherapy 59, no. 5 (2015): 2496–2507, 10.1128/AAC.04958-14. PubMed DOI PMC

Ciesek S., Steinmann E., Wedemeyer H., et al., “Cyclosporine A Inhibits Hepatitis C Virus Nonstructural Protein 2 Through Cyclophilin A,” Hepatology 50, no. 5 (2009): 1638–1645, 10.1002/hep.23281. PubMed DOI

Fernandes F., Poole D. S., Hoover S., et al., “Sensitivity of Hepatitis C Virus to Cyclosporine A Depends on Nonstructural Proteins NS5A and NS5B,” Hepatology 46, no. 4 (2007): 1026–1033, 10.1002/hep.21809. PubMed DOI

Chatterji U., Lim P., Bobardt M. D., et al., “HCV Resistance to Cyclosporin A Does Not Correlate With a Resistance of the NS5A–Cyclophilin A Interaction to Cyclophilin Inhibitors,” Journal of Hepatology 53, no. 1 (2010): 50–56, 10.1016/j.jhep.2010.01.041. PubMed DOI PMC

Liu Z., Yang F., Robotham J. M., and Tang H., “Critical Role of Cyclophilin A and Its Prolyl‐Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex,” Journal of Virology 83, no. 13 (2009): 6554–6565, 10.1128/JVI.02550-08. PubMed DOI PMC

Kaul A., Stauffer S., Berger C., et al., “Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics,” PLoS Pathogens 5, no. 8 (2009): e1000546, 10.1371/journal.ppat.1000546. PubMed DOI PMC

Madan V., Paul D., Lohmann V., and Bartenschlager R., “Inhibition of HCV Replication by Cyclophilin Antagonists Is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation,” Gastroenterology 146, no. 5 (2014): 1361–1372, 10.1053/j.gastro.2014.01.055. PubMed DOI

Foster T. L., Gallay P., Stonehouse N. J., and Harris M., “Cyclophilin A Interacts With Domain II of Hepatitis C Virus NS5A and Stimulates RNA Binding in an Isomerase‐Dependent Manner,” Journal of Virology 85, no. 14 (2011): 7460–7464, 10.1128/JVI.00393-11. PubMed DOI PMC

Gallay P., Ure D., Bobardt M., et al., “The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAG in Transgenic Mice,” PLoS One 14, no. 6 (2019): e0217433, 10.1371/journal.pone.0217433. PubMed DOI PMC

Han J., Lee M. K., Jang Y., Cho W.‐J., and Kim M., “Repurposing of Cyclophilin A Inhibitors as Broad‐Spectrum Antiviral Agents,” Drug Discovery Today 27, no. 7 (2022): 1895–1912, 10.1016/j.drudis.2022.05.016. PubMed DOI PMC

Phillips S., “Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production,” Gastroenterology 2014 148, no. 2 (2014): 403–414.e7, 10.1053/j.gastro.2014.10.004. PubMed DOI PMC

Watashi K., Sluder A., Daito T., et al., “Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP),” Hepatology 59, no. 5 (2014): 1726–1737, 10.1002/hep.26982. PubMed DOI PMC

Vidotto A., Morais A. T. S., Ribeiro M. R., et al., “Systems Biology Reveals NS4B‐Cyclophilin A Interaction: A New Target to Inhibit YFV Replication,” Journal of Proteome Research 16, no. 4 (2017): 1542–1555, 10.1021/acs.jproteome.6b00933. PubMed DOI

de Wilde A. H., Pham U., Posthuma C. C., and Snijder E. J., “Cyclophilins and Cyclophilin Inhibitors in Nidovirus Replication,” Virology 522 (2018): 46–55, 10.1016/j.virol.2018.06.011. PubMed DOI PMC

Neuman B. W., Joseph J. S., Saikatendu K. S., et al., “Proteomics Analysis Unravels the Functional Repertoire of Coronavirus Nonstructural Protein 3,” Journal of Virology 82, no. 11 (2008): 5279–5294, 10.1128/JVI.02631-07. PubMed DOI PMC

Luo C., Luo H., Zheng S., et al., “Nucleocapsid Protein of SARS Coronavirus Tightly Binds to Human Cyclophilin A,” Biochemical and Biophysical Research Communications 321 (2004): 557–565, 10.1016/j.bbrc.2004.07.003. PubMed DOI PMC

Lutomski C. A., El‐Baba T. J., Bolla J. R., and Robinson C. V., “Multiple Roles of SARS‐CoV‐2 N Protein Facilitated by Proteoform‐Specific Interactions With RNA, Host Proteins, and Convalescent Antibodies,” JACS Au 1, no. 8 (2021): 1147–1157, 10.1021/jacsau.1c00139. PubMed DOI PMC

Ma‐Lauer Y., Zheng Y., Malešević M., von Brunn B., Fischer G., and von Brunn A., “Influences of Cyclosporin A and Non‐Immunosuppressive Derivatives on Cellular Cyclophilins and Viral Nucleocapsid Protein During Human Coronavirus 229E Replication,” Antiviral Research 173 (2020): 104620, 10.1016/j.antiviral.2019.104620. PubMed DOI PMC

Pfefferle S., Schöpf J., Kögl M., et al., “The SARS‐Coronavirus‐Host Interactome: Identification of Cyclophilins as Target for Pan‐Coronavirus Inhibitors,” PLoS Pathogens 7, no. 10 (2011): e1002331, 10.1371/journal.ppat.1002331. PubMed DOI PMC

Carbajo‐Lozoya J., Ma‐Lauer Y., Malešević M., et al., “Human Coronavirus NL63 Replication Is Cyclophilin A‐Dependent and Inhibited by Non‐Immunosuppressive Cyclosporine A‐Derivatives Including Alisporivir,” Virus Research 184 (2014): 44–53, 10.1016/j.virusres.2014.02.010. PubMed DOI PMC

Softic L., Brillet R., Berry F., et al., “Inhibition of SARS‐CoV‐2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025),” Antimicrobial Agents and Chemotherapy 64, no. 7 (2020): e00876‐20, 10.1128/AAC.00876-20. PubMed DOI PMC

Sheng X., Zhu F., Peng H., et al., “Host Cyclophilin A Facilitates SARS‐CoV‐2 Infection by Binding and Stabilizing Spike on Virions,” Signal Transduction and Targeted Therapy 8 (2023): 459, 10.1038/s41392-023-01719-7. PubMed DOI PMC

Mamatis J. E., Gallardo‐Flores C. E., Sangwan U., Tooley T. H., Walsh T., and Colpitts C. C., “Induction of Antiviral Gene Expression by Cyclosporine A, but Not Inhibition of Cyclophilin A or B, Contributes to Its Restriction of Human Coronavirus 229E Infection in a Lung Epithelial Cell Line,” Antiviral Research 219 (2023): 105730, 10.1016/j.antiviral.2023.105730. PubMed DOI

Jin Z.‐G., Melaragno M. G., Liao D.‐F., et al., “Cyclophilin A Is a Secreted Growth Factor Induced by Oxidative Stress,” Circulation Research 87, no. 9 (2000): 789–796, 10.1161/01.RES.87.9.789. PubMed DOI

Griendling K. K. and FitzGerald G. A., “Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS,” Circulation 108, no. 16 (2003): 1912–1916, 10.1161/01.CIR.0000093660.86242.BB. PubMed DOI

Anagnostakos J. and Lal B. K., “Abdominal Aortic Aneurysms,” Progress in Cardiovascular Diseases 65 (2021): 34–43, 10.1016/j.pcad.2021.03.009. PubMed DOI

Satoh K., Nigro P., Matoba T., et al., “Cyclophilin A Enhances Vascular Oxidative Stress and the Development of Angiotensin II–Induced Aortic Aneurysms,” Nature Medicine 15, no. 6 (2009): 649–656, 10.1038/nm.1958. PubMed DOI PMC

Demyanets S., Konya V., Kastl S. P., et al., “Interleukin‐33 Induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques,” Arteriosclerosis, Thrombosis, and Vascular Biology 31, no. 9 (2011): 2080–2089, 10.1161/ATVBAHA.111.231431. PubMed DOI

Adam van der Vliet J. and Boll A. P., “Abdominal Aortic Aneurysm,” Lancet 349, no. 9055 (1997): 863–866, 10.1016/s0140-6736(96)07282-0. PubMed DOI

Prins P. A., Perati P. R., Kon V., et al., “Benzo[a]Pyrene Potentiates the Pathogenesis of Abdominal Aortic Aneurysms in Apolipoprotein E Knockout Mice,” Cellular Physiology and Biochemistry 29, no. 1–2 (2012): 121–130, 10.1159/000337593. PubMed DOI PMC

Piechota‐Polanczyk A., Demyanets S., Nykonenko O., et al., “Decreased Tissue Levels of Cyclophilin A, a Cyclosporine A Target and Phospho‐ERK1/2 in Simvastatin Patients With Abdominal Aortic Aneurysm,” European Journal of Vascular and Endovascular Surgery 45, no. 6 (2013): 682–688, 10.1016/j.ejvs.2013.02.015. PubMed DOI

Hansson G. K. and Libby P., “The Immune Response in Atherosclerosis: A Double‐Edged Sword,” Nature Reviews Immunology 6, no. 7 (2006): 508–519, 10.1038/nri1882. PubMed DOI

Nigro P., Satoh K., O'Dell M. R., et al., “Cyclophilin A Is an Inflammatory Mediator That Promotes Atherosclerosis in Apolipoprotein E–Deficient Mice,” Journal of Experimental Medicine 208, no. 1 (2011): 53–66, 10.1084/jem.20101174. PubMed DOI PMC

Kim J.‐Y., Kim W.‐J., Kim H., Suk K., and Lee W.‐H., “The Stimulation of CD147 Induces MMP‐9 Expression Through ERK and NF‐ΚB in Macrophages: Implication for Atherosclerosis,” Immune Network 9, no. 3 (2009): 90–97, 10.4110/in.2009.9.3.90. PubMed DOI PMC

Yuan W., Ge H., and He B., “Pro‐Inflammatory Activities Induced by CyPA–EMMPRIN Interaction in Monocytes,” Atherosclerosis 213 (2010): 415–421, 10.1016/j.atherosclerosis.2010.09.033. PubMed DOI

Seizer P., Gawaz M., and May A. E., “Cyclophilin A and EMMPRIN (CD147) in Cardiovascular Diseases,” Cardiovascular Research 102 (2014): 17–23, 10.1093/cvr/cvu035. PubMed DOI

Seeman P. and Seeman N., “Alzheimer's Disease: β‐Amyloid Plaque Formation in Human Brain,” Synapse 65, no. 12 (2011): 1289–1297, 10.1002/syn.20957. PubMed DOI

Coedert M., Spillantini M. C., Rutherford D., and Crowther R. A., “Multiple Lsoforms of Human Microtubule‐Associated Protein Tau: Sequences and Localization in Neurofibrillah Tangles of Alzheimer's Disease.” PubMed

Huang X., Moir R. D., Tanzi R. E., Bush A. I., and Rogers J. T., “Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology,” Annals of the New York Academy of Sciences 1012, no. 1 (2004): 153–163, 10.1196/annals.1306.012. PubMed DOI

Reddy P. H., Manczak M., Mao P., Calkins M. J., Reddy A. P., and Shirendeb U., “Amyloid‐β and Mitochondria in Aging and Alzheimer's Disease: Implications for Synaptic Damage and Cognitive Decline,” Journal of Alzheimer's Disease 20, no. s2 (2010): S499–S512, 10.3233/JAD-2010-100504. PubMed DOI PMC

Wang X., Wang W., Li L., Perry G., Lee H., and Zhu X., “Oxidative Stress and Mitochondrial Dysfunction in Alzheimer's Disease,” Biochimica et Biophysica Acta (BBA) ‐ Molecular Basis of Disease 1842, no. 8 (2014): 1240–1247, 10.1016/j.bbadis.2013.10.015. PubMed DOI PMC

Chow V. W., Mattson M. P., Wong P. C., and Gleichmann M., “An Overview of APP Processing Enzymes and Products,” NeuroMolecular Medicine 12, no. 1 (2010): 1–12, 10.1007/s12017-009-8104-z. PubMed DOI PMC

Melo A., Monteiro L., Lima R. M. F., de Oliveira D. M., de Cerqueira M. D., and El‐Bachá R. S., “Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives,” Oxidative Medicine and Cellular Longevity 2011 (2011): 1–14, 10.1155/2011/467180. PubMed DOI PMC

Bell R. D., Winkler E. A., Singh I., et al., “Apolipoprotein E Controls Cerebrovascular Integrity via Cyclophilin A,” Nature 485, no. 7399 (2012): 512–516, 10.1038/nature11087. PubMed DOI PMC

Sweeney M. D., Ayyadurai S., and Zlokovic B. V., “Pericytes of the Neurovascular Unit: Key Functions and Signaling Pathways,” Nature Neuroscience 19 (2016): 771–783, 10.1038/nn.4288. PubMed DOI PMC

Hidayati H. B. and Pranata C. A., “Pathogenesis and Management of Pain in Amyotrophic Lateral Sclerosis,” Anaesthesia, Pain & Intensive Care 25, no. 2 (2021): 236–243, 10.35975/apic.v25i2.1478. DOI

Cookson M. R., Menzies F. M., Manning P., et al., “Cu/Zn Superoxide Dismutase (SOD1) Mutations Associated With Familial Amyotrophic Lateral Sclerosis (ALS) Affect Cellular Free Radical Release in the Presence of Oxidative Stress,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 3, no. 2 (2002): 75–85, 10.1080/146608202760196048. PubMed DOI

Strong M. J., Kesavapany S., and Pant H. C., “The Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy?,” Journal of Neuropathology and Experimental Neurology 64, no. 8 (2005): 649–664, 10.1097/01.jnen.0000173889.71434.ea. PubMed DOI

Basso M., Samengo G., Nardo G., et al., “Characterization of Detergent‐Insoluble Proteins in ALS Indicates a Causal Link Between Nitrative Stress and Aggregation in Pathogenesis,” PLoS One 4, no. 12 (2009): e8130, 10.1371/journal.pone.0008130. PubMed DOI PMC

Pasetto L., Pozzi S., Castelnovo M., et al., “Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis,” Journal of neuroscience 37, no. 6 (2017): 1413–1427, 10.1523/JNEUROSCI.2462-16.2016. PubMed DOI PMC

Balsley M. A., Malesevic M., Stemmy E. J., et al., “A Cell‐Impermeable Cyclosporine A Derivative Reduces Pathology in a Mouse Model of Allergic Lung Inflammation,” Journal of Immunology 185, no. 12 (2010): 7663–7670, 10.4049/jimmunol.1001707. PubMed DOI PMC

Malesevic M., Gutknecht D., Prell E., et al., “Anti‐Inflammatory Effects of Extracellular Cyclosporins Are Exclusively Mediated by CD147,” Journal of Medicinal Chemistry 56, no. 18 (2013): 7302–7311, 10.1021/jm4007577. PubMed DOI

Zhang M., Dai C., Zhu H., et al., “Cyclophilin A Promotes Human Hepatocellular Carcinoma Cell Metastasis via Regulation of MMP3 and MMP9,” Molecular and Cellular Biochemistry 357, no. 1–2 (2011): 387–395, 10.1007/s11010-011-0909-z. PubMed DOI

Lim S. O., Park S.‐J., Kim W., et al., “Proteome Analysis of Hepatocellular Carcinoma,” Biochemical and Biophysical Research Communications 291, no. 4 (2002): 1031–1037, 10.1006/bbrc.2002.6547. PubMed DOI

Chen Y.‐I. G., Moore R. E., Ge H. Y., Young M. K., Lee T. D., and Stevens S. W., “Proteomic Analysis of in Vivo‐Assembled Pre‐MRNA Splicing Complexes Expands the Catalog of Participating Factors,” Nucleic Acids Research 35, no. 12 (2007): 3928–3944, 10.1093/nar/gkm347. PubMed DOI PMC

Li M., Zhai Q., Bharadwaj U., et al., “Cyclophilin A Is Overexpressed in Human Pancreatic Cancer Cells and Stimulates Cell Proliferation Through CD147,” Cancer 106, no. 10 (2006): 2284–2294, 10.1002/cncr.21862. PubMed DOI

Li L., Tang W., Wu X., et al., “HAb18G/CD147 Promotes PSTAT3‐Mediated Pancreatic Cancer Development via CD44s,” Clinical Cancer Research 19, no. 24 (2013): 6703–6715, 10.1158/1078-0432.CCR-13-0621. PubMed DOI PMC

Li M., Wang H., Li F., Fisher W. E., Chen C., and Yao Q., “Effect of Cyclophilin A on Gene Expression in Human Pancreatic Cancer Cells,” American Journal of Surgery 190, no. 5 (2005): 739–745, 10.1016/j.amjsurg.2005.07.013. PubMed DOI

Yang H., Chen J., Yang J., Qiao S., Zhao S., and Yu L., “Cyclophilin A Is Upregulated in Small Cell Lung Cancer and Activates ERK1/2 Signal,” Biochemical and Biophysical Research Communications 361, no. 3 (2007): 763–767, 10.1016/j.bbrc.2007.07.085. PubMed DOI

Qi Y.‐J., He Q.‐Y., Ma Y.‐F., et al., “Proteomic Identification of Malignant Transformation‐Related Proteins in Esophageal Squamous Cell Carcinoma,” Journal of Cellular Biochemistry 104, no. 5 (2008): 1625–1635, 10.1002/jcb.21727. PubMed DOI

Li Z., Min W., and Gou J., “Knockdown of Cyclophilin A Reverses Paclitaxel Resistance in Human Endometrial Cancer Cells via Suppression of MAPK Kinase Pathways,” Cancer Chemotherapy and Pharmacology 72, no. 5 (2013): 1001–1011, 10.1007/s00280-013-2285-8. PubMed DOI

Li Z., Gou J., and Xu J., “Down‐Regulation of Focal Adhesion Signaling in Response to Cyclophilin A Knockdown in Human Endometrial Cancer Cells, Implicated by CDNA Microarray Analysis,” Gynecologic Oncology 131, no. 1 (2013): 191–197, 10.1016/j.ygyno.2013.07.095. PubMed DOI

Hathout Y., Riordan K., Gehrmann M., and Fenselau C., “Differential Protein Expression in the Cytosol Fraction of an MCF‐7 Breast Cancer Cell Line Selected for Resistance Toward Melphalan,” Journal of Proteome Research 1, no. 5 (2002): 435–442, 10.1021/pr020006i. PubMed DOI

Zheng J., Koblinski J. E., Dutson L. V., Feeney Y. B., and Clevenger C. V., “Prolyl Isomerase Cyclophilin A Regulation of Janus‐Activated Kinase 2 and the Progression of Human Breast Cancer,” Cancer Research 68, no. 19 (2008): 7769–7778, 10.1158/0008-5472.CAN-08-0639. PubMed DOI

Han J. M. and Jung H. J., “Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy,” International Journal of Molecular Sciences 23, no. 16 (2022): 9341, 10.3390/ijms23169341. PubMed DOI PMC

Al‐Ghoul M., Brück T. B., Lauer‐Fields J. L., et al., “Comparative Proteomic Analysis of Matched Primary and Metastatic Melanoma Cell Lines,” Journal of Proteome Research 7, no. 9 (2008): 4107–4118, 10.1021/pr800174k. PubMed DOI

Howard B. A., Furumai R., Campa M. J., et al., “Stable RNA Interference–Mediated Suppression of Cyclophilin A Diminishes Non–Small‐Cell Lung Tumor Growth PubMed DOI

Hamilton G., “Cyclophilin A as a Target of Cisplatin Chemosensitizers,” Current Cancer Drug Targets 14, no. 1 (2014): 46–58, 10.2174/15680096113136660109. PubMed DOI

Lee J., “Novel Combinational Treatment of Cisplatin With Cyclophilin a Inhibitors in Human Heptocellular Carcinomas,” Archives of Pharmacal Research 33, no. 9 (2010): 1401–1409, 10.1007/s12272-010-0914-x. PubMed DOI

T.M. Lavin P. and M. Mc Gee M., “Cyclophilin Function in Cancer; Lessons From Virus Replication,” Current Molecular Pharmacology 9, no. 2 (2015): 148–164, 10.2174/1874467208666150519115443. PubMed DOI

Ure D. R., Trepanier D. J., Mayo P. R., and Foster R. T., “Cyclophilin Inhibition as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH),” Expert Opinion on Investigational Drugs 29, no. 2 (2020): 163–178, 10.1080/13543784.2020.1703948. PubMed DOI

Trachtenberg A., Pushkarsky T., Heine S., Constant S., Brichacek B., and Bukrinsky M., “The Level of CD147 Expression Correlates With Cyclophilin‐Induced Signalling and Chemotaxis,” BMC Research Notes 4 (2011): 396, 10.1186/1756-0500-4-396. PubMed DOI PMC

Schlegel J., Redzic J. S., Porter C. C., et al., “Solution Characterization of the Extracellular Region of CD147 and Its Interaction With Its Enzyme Ligand Cyclophilin A,” Journal of Molecular Biology 391, no. 3 (2009): 518–535, 10.1016/j.jmb.2009.05.080. PubMed DOI PMC

Yurchenko V., Constant S., Eisenmesser E., and Bukrinsky M., “Cyclophilin–CD147 Interactions: A New Target for Anti‐Inflammatory Therapeutics,” Clinical and Experimental Immunology 160, no. 3 (2010): 305–317, 10.1111/j.1365-2249.2010.04115.x. PubMed DOI PMC

Iordanskaia T., Malesevic M., Fischer G., Pushkarsky T., Bukrinsky M., and Nadler E. P., “Targeting Extracellular Cyclophilins Ameliorates Disease Progression in Experimental Biliary Atresia,” Molecular Medicine 21 (2015): 657–664, 10.2119/molmed.2015.00076. PubMed DOI PMC

Price E. R., Zydowsky L. D., Jin M. J., Baker C. H., McKeon F. D., and Walsh C. T., “Human Cyclophilin B: A Second Cyclophilin Gene Encodes a Peptidyl‐Prolyl Isomerase With a Signal Sequence,” Proceedings of the National Academy of Sciences 88, no. 5 (1991): 1903–1907, 10.1073/pnas.88.5.1903. PubMed DOI PMC

Mikol V., Kallen J., and Walkinshaw M. D., “X‐Ray Structure of a Cyclophilin B/Cyclosporin Complex: Comparison With Cyclophilin A and Delineation of Its Calcineurin‐Binding Domain,” Proceedings of the National Academy of Sciences 91, no. 11 (1994): 5183–5186, 10.1073/pnas.91.11.5183. PubMed DOI PMC

Etzkorn F. A., Chang Z., Stolz L. A., and Walsh C. T., “Cyclophilin Residues That Affect Noncompetitive Inhibition of the Protein Serine Phosphatase Activity of Calcineurin by the Cyclophilin.cntdot.Cyclosporin A Complex,” Biochemistry 33, no. 9 (1994): 2380–2388, 10.1021/bi00175a005. PubMed DOI

Terajima M., Taga Y., Cabral W. A., et al., “Cyclophilin B Deficiency Causes Abnormal Dentin Collagen Matrix,” Journal of Proteome Research 16, no. 8 (2017): 2914–2923, 10.1021/acs.jproteome.7b00190. PubMed DOI

von Bülow U. and Bram R. J., “NF‐AT Activation Induced by a CAML‐Interacting Member of the Tumor Necrosis Factor Receptor Superfamily,” Science 278, no. 5335 (1997): 138–141, 10.1126/science.278.5335.138. PubMed DOI

Obata Y., Yamamoto K., Miyazaki M., Shimotohno K., Kohno S., and Matsuyama T., “Role of Cyclophilin B in Activation of Interferon Regulatory Factor‐3,” Journal of Biological Chemistry 280, no. 18 (2005): 18355–18360, 10.1074/jbc.M501684200. PubMed DOI

Rycyzyn M. A., Reilly S. C., O'malley K., and Clevenger C. V., “Role of Cyclophilin B in Prolactin Signal Transduction and Nuclear Retrotranslocation,” Molecular Endocrinology (Baltimore, MD) 14, no. 8 (2000): 1175–1186, 10.1210/mend.14.8.0508. PubMed DOI

Watashi K., Ishii N., Hijikata M., et al., “Cyclophilin B Is a Functional Regulator of Hepatitis C Virus RNA Polymerase,” Molecular Cell 19, no. 1 (2005): 111–122, 10.1016/j.molcel.2005.05.014. PubMed DOI

Kambara H., Tani H., Mori Y., et al., “Involvement of Cyclophilin B in the Replication of Japanese Encephalitis Virus,” Virology 412, no. 1 (2011): 211–219, 10.1016/j.virol.2011.01.011. PubMed DOI

Bienkowska‐Haba M., Patel H. D., and Sapp M., “Target Cell Cyclophilins Facilitate Human Papillomavirus Type 16 Infection,” PLoS Pathogens 5, no. 7 (2009): e1000524, 10.1371/journal.ppat.1000524. PubMed DOI PMC

Betarbet R., Sherer T. B., MacKenzie G., Garcia‐Osuna M., Panov A. V., and Greenamyre J. T., “Chronic Systemic Pesticide Exposure Reproduces Features of Parkinson's Disease,” Nature Neuroscience 3, no. 12 (2000): 1301–1306, 10.1038/81834. PubMed DOI

Oh Y., Jeong K., Kim K., et al., “Cyclophilin B Protects SH‐SY5Y Human Neuroblastoma Cells Against MPP+ ‐Induced Neurotoxicity via JNK Pathway,” Biochemical and Biophysical Research Communications 478, no. 3 (2016): 1396–1402, 10.1016/j.bbrc.2016.08.135. PubMed DOI

Choi J. W., Sutor S. L., Lindquist L., et al., “Severe Osteogenesis Imperfecta in Cyclophilin B–Deficient Mice,” PLoS Genetics 5, no. 12 (2009): e1000750, 10.1371/journal.pgen.1000750. PubMed DOI PMC

Mei F. and Tu Y., “Cyclophilin B Enhances the Proliferation and Differentiation of MC3T3‐E1 Cells via JAK2/STAT3 Signaling Pathway,” Biotechnology & Biotechnological Equipment 33, no. 1 (2019): 1590–1598, 10.1080/13102818.2019.1684842. DOI

DeBoer J., Madson C. J., and Belshan M., “Cyclophilin B Enhances HIV‐1 Infection,” Virology 489 (2016): 282–291, 10.1016/j.virol.2015.12.015. PubMed DOI PMC

Akiyama H., Yoshinaga H., Tanaka T., et al., “Effects of Cyclosporin A on Hepatitis C Virus Infection in Bone Marrow Transplant Patients,” Bone Marrow Transplantation 20, no. 11 (1997): 993–995, 10.1038/sj.bmt.1700996. PubMed DOI

Nakagawa M., Sakamoto N., Enomoto N., et al., “Specific Inhibition of Hepatitis C Virus Replication by Cyclosporin A,” Biochemical and Biophysical Research Communications 313, no. 1 (2004): 42–47, 10.1016/j.bbrc.2003.11.080. PubMed DOI

Zhang K., Lu Z., Shang Y., et al., “Diagnosis and Phylogenetic Analysis of Orf Virus From Goats in China: A Case Report,” Virology Journal 7, no. 1 (2010): 78, 10.1186/1743-422X-7-78. PubMed DOI PMC

Zhao K., Li J., He W., et al., “Cyclophilin B Facilitates the Replication of Orf Virus,” Virology Journal 14, no. 1 (2017): 114, 10.1186/s12985-017-0781-x. PubMed DOI PMC

Murphy M. P. and LeVine H., “Alzheimer's Disease and the Amyloid‐β Peptide,” Journal of Alzheimer's Disease 19, no. 1 (2010): 311–323, 10.3233/JAD-2010-1221. PubMed DOI PMC

Suen K.‐C., Lin K.‐F., Elyaman W., So K.‐F., Chuen‐Chung Chang R., and Hugon J., “Reduction of Calcium Release From the Endoplasmic Reticulum Could Only Provide Partial Neuroprotection Against Beta‐Amyloid Peptide Toxicity,” Journal of Neurochemistry 87, no. 6 (2003): 1413–1426, 10.1111/j.1471-4159.2003.02259.x. PubMed DOI

Fukui K., Takatsu H., Shinkai T., Suzuki S., Abe K., and Urano S., “Appearance of Amyloid β‐Like Substances and Delayed‐Type Apoptosis in Rat Hippocampus CA1 Region Through Aging and Oxidative Stress,” Journal of Alzheimer's Disease 8, no. 3 (2005): 299–309, 10.3233/JAD-2005-8309. PubMed DOI

Kadowaki H., Nishitoh H., Urano F., et al., “Amyloid β Induces Neuronal Cell Death Through ROS‐Mediated ASK1 Activation,” Cell Death & Differentiation 12, no. 1 (2005): 19–24, 10.1038/sj.cdd.4401528. PubMed DOI

Oh Y., Kim E. Y., Kim Y., et al., “Neuroprotective Effects of Overexpressed Cyclophilin B Against Aβ‐Induced Neurotoxicity in PC12 Cells,” Free Radical Biology and Medicine 51, no. 4 (2011): 905–920, 10.1016/j.freeradbiomed.2011.05.036. PubMed DOI

Kim J., Choi T. G., Ding Y., et al., “Overexpressed Cyclophilin B Suppresses Apoptosis Associated With ROS and Ca2+ Homeostasis After ER Stress,” Journal of Cell Science 121, no. 21 (2008): 3636–3648, 10.1242/jcs.028654. PubMed DOI PMC

Fang F., Zheng J., Galbaugh T. L., et al., “Cyclophilin B as a Co‐Regulator of Prolactin‐Induced Gene Expression and Function in Breast Cancer Cells,” Journal of Molecular Endocrinology 44, no. 6 (2010): 319–329, 10.1677/JME-09-0140. PubMed DOI PMC

Kim K., Kim H., Jeong K., et al., “Release of Overexpressed CypB Activates ERK Signaling Through CD147 Binding for Hepatoma Cell Resistance to Oxidative Stress,” Apoptosis 17, no. 8 (2012): 784–796, 10.1007/s10495-012-0730-5. PubMed DOI

Kim K., Kim H., Jeong K., et al., “Correction To: Release of Overexpressed CypB Activates ERK Signaling Through CD147 Binding for Hepatoma Cell Resistance to Oxidative Stress,” Apoptosis 23, no. 11–12 (2018): 707–709, 10.1007/s10495-018-1486-3. PubMed DOI

Jeong K., Kim K., Kim H., et al., “Hypoxia Induces Cyclophilin B Through the Activation of Transcription Factor 6 in Gastric Adenocarcinoma Cells,” Oncology Letters 9, no. 6 (2015): 2854–2858, 10.3892/ol.2015.3102. PubMed DOI PMC

Meng D. Q., Li P. L., and Xie M., “Expression and Role of Cyclophilin B in Stomach Cancer,” Genetics and Molecular Research 14, no. 2 (2015): 5346–5354, 10.4238/2015.May.22.5. PubMed DOI

Lee Y.‐S., Jeong S., Kim K.‐Y., et al., “Honokiol Inhibits Hepatoma Carcinoma Cell Migration Through Downregulated Cyclophilin B Expression,” Biochemical and Biophysical Research Communications 552 (2021): 44–51, 10.1016/j.bbrc.2021.03.011. PubMed DOI

Schneider H., Charara N., Schmitz R., et al., “Human Cyclophilin C: Primary Structure, Tissue Distribution, and Determination of Binding Specificity for Cyclosporins,” Biochemistry 33, no. 27 (1994): 8218–8224, 10.1021/bi00193a007. PubMed DOI

Friedman J. and Weissman I., “Two Cytoplasmic Candidates for Immunophilin Action Are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Absence of CsA,” Cell 66, no. 4 (1991): 799–806, 10.1016/0092-8674(91)90123-G. PubMed DOI

Bram R. J., Hung D. T., Martin P. K., Schreiber S. L., and Crabtree G. R., “Identification of the Immunophilins Capable of Mediating Inhibition of Signal Transduction by Cyclosporin A and FK506: Roles of Calcineurin Binding and Cellular Location,” Molecular and Cellular Biology 13, no. 8 (1993): 4760–4769, 10.1128/mcb.13.8.4760-4769.1993. PubMed DOI PMC

Stocki P., Chapman D. C., Beach L. A., and Williams D. B., “Depletion of Cyclophilins B and C Leads to Dysregulation of Endoplasmic Reticulum Redox Homeostasis,” Journal of Biological Chemistry 289, no. 33 (2014): 23086–23096, 10.1074/jbc.M114.570911. PubMed DOI PMC

Yamaguchi R., Hosaka M., Torii S., et al., “Cyclophilin C‐Associated Protein Regulation of Phagocytic Functions via NFAT Activation in Macrophages,” Brain Research 1397 (2011): 55–65, 10.1016/j.brainres.2011.03.036. PubMed DOI

Alfonso A., Bayón J., Gegunde S., et al., “High Serum Cyclophilin C Levels as a Risk Factor Marker for Coronary Artery Disease,” Scientific Reports 9, no. 1 (2019): 10576, 10.1038/s41598-019-46988-x. PubMed DOI PMC

Fujimoto K., Chen Y., Polonsky K. S., and Dorn G. W., “Targeting Cyclophilin D and the Mitochondrial Permeability Transition Enhances β‐Cell Survival and Prevents Diabetes in Pdx1 Deficiency,” Proceedings of the National Academy of Sciences 107, no. 22 (2010): 10214–10219, 10.1073/pnas.0914209107. PubMed DOI PMC

Ramachandran S., Venugopal A., Kutty V. R., et al., “Plasma Level of Cyclophilin A Is Increased in Patients With Type 2 Diabetes Mellitus and Suggests Presence of Vascular Disease,” Cardiovascular Diabetology 13, no. 1 (2014): 38, 10.1186/1475-2840-13-38. PubMed DOI PMC

McClements L., Annett S., Yakkundi A., and Robson T., “The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases,” Current Molecular Pharmacology 9, no. 2 (2015): 165–179, 10.2174/1874467208666150519115729. PubMed DOI

Zhang H., Fan Q., Xie H., et al., “Elevated Serum Cyclophilin B Levels Are Associated With the Prevalence and Severity of Metabolic Syndrome,” Frontiers in Endocrinology 8 (2017): 360, 10.3389/fendo.2017.00360. PubMed DOI PMC

Shimizu T., Imai H., Seki K., et al., “Cyclophilin C‐Associated Protein and Cyclophilin C MRNA Are Upregulated in Penumbral Neurons and Microglia After Focal Cerebral Ischemia,” Journal of Cerebral Blood Flow & Metabolism 25, no. 3 (2005): 325–337, 10.1038/sj.jcbfm.9600029. PubMed DOI

Chapman D. C., Stocki P., and Williams D. B., “Cyclophilin C Participates in the US2‐Mediated Degradation of Major Histocompatibility Complex Class I Molecules,” PLoS One 10, no. 12 (2015): e0145458, 10.1371/journal.pone.0145458. PubMed DOI PMC

Taylor P., Dornan J., Carrello A., Minchin R. F., Ratajczak T., and Walkinshaw M. D., “Two Structures of Cyclophilin 40: Folding and Fidelity in the TPR Domains. 8.” PubMed

Duina A. A., Chang H.‐C. J., Marsh J. A., Lindquist S., and Gaber R. F., “A Cyclophilin Function in Hsp90‐Dependent Signal Transduction,” Science 274, no. 5293 (1996): 1713–1715, 10.1126/science.274.5293.1713. PubMed DOI

Johnson J. L. and Craig E. A., “Protein Folding In Vivo: Unraveling Complex Pathways,” Cell 90, no. 2 (1997): 201–204, 10.1016/S0092-8674(00)80327-X. PubMed DOI

Goto K., Watashi K., Inoue D., Hijikata M., and Shimotohno K., “Identification of Cellular and Viral Factors Related to Anti‐Hepatitis C Virus Activity of Cyclophilin Inhibitor,” Cancer Science 100, no. 10 (2009): 1943–1950, 10.1111/j.1349-7006.2009.01263.x. PubMed DOI PMC

Siegel R. L., Miller K. D., Fuchs H. E., and Jemal A., “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7–33, 10.3322/caac.21708. PubMed DOI

Periyasamy S., Hinds T Jr, Shemshedini L., Shou W., and Sanchez E. R., “FKBP51 and Cyp40 Are Positive Regulators of Androgen‐Dependent Prostate Cancer Cell Growth and the Targets of FK506 and Cyclosporin A,” Oncogene 29, no. 11 (2010): 1691–1701, 10.1038/onc.2009.458. PubMed DOI PMC

Halestrap A. P. and Davidson A. M., “Inhibition of Ca2+‐Induced Large‐Amplitude Swelling of Liver and Heart Mitochondria by Cyclosporin Is Probably Caused by the Inhibitor Binding to Mitochondrial‐Matrix Peptidyl‐Prolyl PubMed DOI PMC

Shang W., Gao H., Lu F., et al., “Cyclophilin D Regulates Mitochondrial Flashes and Metabolism in Cardiac Myocytes,” Journal of Molecular and Cellular Cardiology 91 (2016): 63–71, 10.1016/j.yjmcc.2015.10.036. PubMed DOI

Laker R. C., Taddeo E. P., Akhtar Y. N., Zhang M., Hoehn K. L., and Yan Z., “The Mitochondrial Permeability Transition Pore Regulator Cyclophilin D Exhibits Tissue‐Specific Control of Metabolic Homeostasis,” PLoS One 11, no. 12 (2016): e0167910, 10.1371/journal.pone.0167910. PubMed DOI PMC

Elrod J. W. and Molkentin J. D., “Physiologic Functions of Cyclophilin D and the Mitochondrial Permeability Transition Pore,” Circulation Journal 77, no. 5 (2013): 1111–1122, 10.1253/circj.CJ-13-0321. PubMed DOI PMC

Amanakis G. and Murphy E., “Cyclophilin D: An Integrator of Mitochondrial Function,” Frontiers in Physiology 11 (2020): 595, 10.3389/fphys.2020.00595. PubMed DOI PMC

Kajitani K., Fujihashi M., Kobayashi Y., Shimizu S., Tsujimoto Y., and Miki K., “Crystal Structure of Human Cyclophilin D in Complex With Its Inhibitor, Cyclosporin A at 0.96‐Å Resolution,” Proteins: Structure, Function, and Bioinformatics 70, no. 4 (2007): 1635–1639, 10.1002/prot.21855. PubMed DOI

Shore E. R., Awais M., Kershaw N. M., et al., “Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis,” Journal of Medicinal Chemistry 59, no. 6 (2016): 2596–2611, 10.1021/acs.jmedchem.5b01801. PubMed DOI

De Simone A., Georgiou C., Ioannidis H., et al., “A Computationally Designed Binding Mode Flip Leads to a Novel Class of Potent Tri‐Vector Cyclophilin Inhibitors,” Chemical Science 10, no. 2 (2019): 542–547, 10.1039/C8SC03831G. PubMed DOI PMC

Peterson A. A., Rangwala A. M., Thakur M. K., et al., “Discovery and Molecular Basis of Subtype‐Selective Cyclophilin Inhibitors,” Nature Chemical Biology 18, no. 11 (2022): 1184–1195, 10.1038/s41589-022-01116-1. PubMed DOI PMC

Briston T., Selwood D. L., Szabadkai G., and Duchen M. R., “Mitochondrial Permeability Transition: A Molecular Lesion With Multiple Drug Targets,” Trends in Pharmacological Sciences 40, no. 1 (2019): 50–70, 10.1016/j.tips.2018.11.004. PubMed DOI

Rao V. K., Carlson E. A., and Yan S. S., “Mitochondrial Permeability Transition Pore Is a Potential Drug Target for Neurodegeneration,” Biochimica et Biophysica Acta (BBA) ‐ Molecular Basis of Disease 1842, no. 8 (2014): 1267–1272, 10.1016/j.bbadis.2013.09.003. PubMed DOI PMC

Waldmeier P., Zimmermann K., Qian T., Tintelnot‐Blomley M., and Lemasters J., “Cyclophilin D as a Drug Target,” Current Medicinal Chemistry 10, no. 16 (2003): 1485–1506, 10.2174/0929867033457160. PubMed DOI

Alam M. R., Baetz D., and Ovize M., “Cyclophilin D and Myocardial Ischemia–Reperfusion Injury: A Fresh Perspective,” Journal of Molecular and Cellular Cardiology 78 (2015): 80–89, 10.1016/j.yjmcc.2014.09.026. PubMed DOI

Bonora M., Patergnani S., Ramaccini D., et al., “Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology,” Biomolecules 10, no. 7 (2020): 998, 10.3390/biom10070998. PubMed DOI PMC

Halestrap A. P. and Richardson A. P., “The Mitochondrial Permeability Transition: A Current Perspective on Its Identity and Role in Ischaemia/Reperfusion Injury,” Journal of Molecular and Cellular Cardiology 78 (2015): 129–141, 10.1016/j.yjmcc.2014.08.018. PubMed DOI

Benek O., Aitken L., Hroch L., Kuca K., Gunn‐Moore F., and Musilek K., “A Direct Interaction Between Mitochondrial Proteins and Amyloid‐β; Peptide and Its Significance for the Progression and Treatment of Alzheimer's Disease,” Current Medicinal Chemistry 22, no. 9 (2015): 1056–1085, 10.2174/0929867322666150114163051. PubMed DOI

Valasani K. R., Sun Q., Fang D., et al., “Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Aβ‐Mediated Mitochondrial Dysfunction,” ACS Medicinal Chemistry Letters 7, no. 3 (2016): 294–299, 10.1021/acsmedchemlett.5b00451. PubMed DOI PMC

Warne J., Pryce G., Hill J. M., et al., “Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects Against Neurodegeneration in Experimental Multiple Sclerosis,” Journal of Biological Chemistry 291, no. 9 (2016): 4356–4373, 10.1074/jbc.M115.700385. PubMed DOI PMC

Sun J., Ren D.‐D., Wan J.‐Y., et al., “Desensitizing Mitochondrial Permeability Transition by ERK‐Cyclophilin D Axis Contributes to the Neuroprotective Effect of Gallic Acid Against Cerebral Ischemia/Reperfusion Injury,” Frontiers in Pharmacology 8 (2017), 10.3389/fphar.2017.00184. PubMed DOI PMC

Bonora M. and Pinton P., “The Mitochondrial Permeability Transition Pore and Cancer: Molecular Mechanisms Involved in Cell Death,” Frontiers in Oncology 4 (2014), 10.3389/fonc.2014.00302. PubMed DOI PMC

Haleckova A., Benek O., Zemanová L., Dolezal R., and Musilek K., “Small‐Molecule Inhibitors of Cyclophilin D as Potential Therapeutics in Mitochondria‐Related Diseases,” Medicinal Research Reviews 42, no. 5 (2022): 1822–1855, 10.1002/med.21892. PubMed DOI

Hausenloy D., Boston‐Griffiths E., and Yellon D., “Cyclosporin A and Cardioprotection: From Investigative Tool to Therapeutic Agent,” British Journal of Pharmacology 165, no. 5 (2012): 1235–1245, 10.1111/j.1476-5381.2011.01700.x. PubMed DOI PMC

Halestrap A. P., “Mitochondria and Reperfusion Injury of the Heart—A Holey Death but Not Beyond Salvation,” Journal of Bioenergetics and Biomembranes 41, no. 2 (2009): 113–121, 10.1007/s10863-009-9206-x. PubMed DOI

Di Lisa F., Carpi A., Giorgio V., and Bernardi P., “The Mitochondrial Permeability Transition Pore and Cyclophilin D in Cardioprotection,” Biochimica et Biophysica Acta (BBA) ‐ Molecular Cell Research 1813, no. 7 (2011): 1316–1322, 10.1016/j.bbamcr.2011.01.031. PubMed DOI

Ikeda G., Matoba T., Ishikita A., et al., “Nanoparticle‐Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia‐Reperfusion Injury,” Journal of the American Heart Association 10, no. 12 (2021): e019521, 10.1161/JAHA.120.019521. PubMed DOI PMC

Baines C. P., Kaiser R. A., Purcell N. H., et al., “Loss of Cyclophilin D Reveals a Critical Role for Mitochondrial Permeability Transition in Cell Death,” Nature 434, no. 7033 (2005): 658–662, 10.1038/nature03434. PubMed DOI

Nakagawa T., Shimizu S., Watanabe T., et al., “Cyclophilin D‐Dependent Mitochondrial Permeability Transition Regulates Some Necrotic but Not Apoptotic Cell Death,” Nature 434, no. 7033 (2005): 652–658, 10.1038/nature03317. PubMed DOI

Lim J. W., Lee J., and Pae A. N., “Mitochondrial Dysfunction and Alzheimer's Disease: Prospects for Therapeutic Intervention,” BMB Reports 53, no. 1 (2020): 47–55, 10.5483/BMBRep.2020.53.1.279. PubMed DOI PMC

Lustbader J. W., Cirilli M., Lin C., et al., “ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease,” Science 304, no. 5669 (2004): 448–452, 10.1126/science.1091230. PubMed DOI

Reddy P. H. and Beal M. F., “Amyloid Beta, Mitochondrial Dysfunction and Synaptic Damage: Implications for Cognitive Decline in Aging and Alzheimer's Disease,” Trends in Molecular Medicine 14, no. 2 (2008): 45–53, 10.1016/j.molmed.2007.12.002. PubMed DOI PMC

Rui Y., Tiwari P., Xie Z., and Zheng J. Q., “Acute Impairment of Mitochondrial Trafficking by β‐Amyloid Peptides in Hippocampal Neurons,” Journal of neuroscience 26, no. 41 (2006): 10480–10487, 10.1523/JNEUROSCI.3231-06.2006. PubMed DOI PMC

Takuma K., Yao J., Huang J., et al., “ABAD Enhances Aβ‐induced Cell Stress via Mitochondrial Dysfunction,” FASEB Journal 19, no. 6 (2005): 1–25, 10.1096/fj.04-2582fje. PubMed DOI

Du H., Guo L., Zhang W., Rydzewska M., and Yan S., “Cyclophilin D Deficiency Improves Mitochondrial Function and Learning/Memory in Aging Alzheimer Disease Mouse Model,” Neurobiology of Aging 32, no. 3 (2011): 398–406, 10.1016/j.neurobiolaging.2009.03.003. PubMed DOI PMC

Du H., Guo L., Fang F., et al., “Cyclophilin D Deficiency Attenuates Mitochondrial and Neuronal Perturbation and Ameliorates Learning and Memory in Alzheimer's Disease,” Nature Medicine 14, no. 10 (2008): 1097–1105, 10.1038/nm.1868. PubMed DOI PMC

Martin L. J., Semenkow S., Hanaford A., and Wong M., “The Mitochondrial Permeability Transition Pore Regulates Parkinson's Disease Development in Mutant α‐Synuclein Transgenic Mice,” Neurobiology of Aging 35, no. 5 (2014): 1132–1152, 10.1016/j.neurobiolaging.2013.11.008. PubMed DOI PMC

Trinh D., Israwi A. R., Arathoon L. R., Gleave J. A., and Nash J. E., “The Multi‐Faceted Role of Mitochondria in the Pathology of Parkinson's Disease,” Journal of Neurochemistry 156, no. 6 (2021): 715–752, 10.1111/jnc.15154. PubMed DOI

Sasaki S. and Iwata M., “Ultrastructural Change of Synapses of Betz Cells in Patients With Amyotrophic Lateral Sclerosis,” Neuroscience Letters 268, no. 1 (1999): 29–32, 10.1016/S0304-3940(99)00374-2. PubMed DOI

Menzies F., “Mitochondrial Involvement in Amyotrophic Lateral Sclerosis,” Neurochemistry International 40, no. 6 (2002): 543–551, 10.1016/S0197-0186(01)00125-5. PubMed DOI

Siklós L., Engelhardt J., Harati Y., Smith R. G., Joó F., and Appel S. H., “Ultrastructural Evidence for Altered Calcium in Motor Nerve Terminals in Amyotrophc Lateral Sclerosis,” Annals of Neurology 39, no. 2 (1996): 203–216, 10.1002/ana.410390210. PubMed DOI

Nicholls D. G., “Mitochondrial Function and Dysfunction in the Cell: Its Relevance to Aging and Aging‐Related Disease,” International Journal of Biochemistry & Cell Biology 34, no. 11 (2002): 1372–1381, 10.1016/S1357-2725(02)00077-8. PubMed DOI

Martin L. J., “The Mitochondrial Permeability Transition Pore: A Molecular Target for Amyotrophic Lateral Sclerosis Therapy,” Biochimica et Biophysica Acta (BBA) ‐ Molecular Basis of Disease 1802, no. 1 (2010): 186–197, 10.1016/j.bbadis.2009.07.009. PubMed DOI PMC

Abu‐El‐Haija M., Gukovskaya A. S., Andersen D. K., et al., “Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop,” Pancreas 47, no. 10 (2018): 1185–1192, 10.1097/MPA.0000000000001175. PubMed DOI PMC

Shalbueva N., Mareninova O. A., Gerloff A., et al., “Effects of Oxidative Alcohol Metabolism on the Mitochondrial Permeability Transition Pore and Necrosis in a Mouse Model of Alcoholic Pancreatitis,” Gastroenterology 144, no. 2 (2013): 437–446, 10.1053/j.gastro.2012.10.037. PubMed DOI PMC

Mukherjee R., Mareninova O. A., Odinokova I. V., et al., “Mechanism of Mitochondrial Permeability Transition Pore Induction and Damage in the Pancreas: Inhibition Prevents Acute Pancreatitis by Protecting Production of ATP,” Gut 65, no. 8 (2016): 1333–1346, 10.1136/gutjnl-2014-308553. PubMed DOI PMC

Tóth E., Maléth J., Závogyán N., et al., “Novel Mitochondrial Transition Pore Inhibitor PubMed DOI

Lambert J. E., Ramos–Roman M. A., Browning J. D., and Parks E. J., “Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease,” Gastroenterology 146, no. 3 (2014): 726–735, 10.1053/j.gastro.2013.11.049. PubMed DOI PMC

Takaishi K., Duplomb L., Wang M.‐Y., Li J., and Unger R. H., “Hepatic Insig‐1 or ‐2 Overexpression Reduces Lipogenesis in Obese Zucker Diabetic Fatty Rats and in Fasted/Refed Normal Rats,” Proceedings of the National Academy of Sciences 101, no. 18 (2004): 7106–7111, 10.1073/pnas.0401715101. PubMed DOI PMC

Begriche K., Massart J., Robin M.‐A., Bonnet F., and Fromenty B., “Mitochondrial Adaptations and Dysfunctions in Nonalcoholic Fatty Liver Disease,” Hepatology 58, no. 4 (2013): 1497–1507, 10.1002/hep.26226. PubMed DOI

Pessayre D. and Fromenty B., “NASH: A Mitochondrial Disease,” Journal of Hepatology 42, no. 6 (2005): 928–940, 10.1016/j.jhep.2005.03.004. PubMed DOI

Wang X., Du H., Shao S., et al., “Cyclophilin D Deficiency Attenuates Mitochondrial Perturbation and Ameliorates Hepatic Steatosis,” Hepatology 68, no. 1 (2018): 62–77, 10.1002/hep.29788. PubMed DOI

Naguib M., Abou Elfotouh M., and Wifi M.‐N., “Elevated Serum Cyclophilin D Level Is Associated With Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients With Diabetes Mellitus,” International Journal of General Medicine 14 (2021): 4665–4675, 10.2147/IJGM.S322986. PubMed DOI PMC

Li X., Yang M., Sun H., et al., “Liver Cyclophilin D Deficiency Inhibits the Progression of Early NASH by Ameliorating Steatosis and Inflammation,” Biochemical and Biophysical Research Communications 594 (2022): 168–176, 10.1016/j.bbrc.2022.01.059. PubMed DOI

Mi H., Kops O., Zimmermann E., Jäschke A., and Tropschug M., “A Nuclear RNA‐Binding Cyclophilin in Human T Cells,” FEBS Letters 398, no. 2–3 (1996): 201–205, 10.1016/S0014-5793(96)01248-3. PubMed DOI

Wang Y., Han R., Zhang W., et al., “Human CyP33 Binds Specifically to MRNA and Binding Stimulates PPiase Activity of HCyP33,” FEBS Letters 582, no. 5 (2008): 835–839, 10.1016/j.febslet.2008.01.055. PubMed DOI

“Structural Genomics Consortium (SGC),” accessed June 22, 2024, www.thesgc.org/.

"RIKEN,” accessed June 22, 2024, http://www.riken.jp/en/.

Wang Z., Song J., Milne T. A., et al., “Pro Isomerization in MLL1 PHD3‐Bromo Cassette Connects H3K4me Readout to CyP33 and HDAC‐Mediated Repression,” Cell 141, no. 7 (2010): 1183–1194, 10.1016/j.cell.2010.05.016. PubMed DOI PMC

Hom R. A., Chang P.‐Y., Roy S., et al., “Molecular Mechanism of MLL PHD3 and RNA Recognition by the Cyp33 RRM Domain,” Journal of Molecular Biology 400, no. 2 (2010): 145–154, 10.1016/j.jmb.2010.04.067. PubMed DOI PMC

Park S., Osmers U., Raman G., Schwantes R. H., Diaz M. O., and Bushweller J. H., “The PHD3 Domain of MLL Acts as a CYP33‐Regulated Switch Between MLL‐Mediated Activation and Repression,” Biochemistry 49, no. 31 (2010): 6576–6586, 10.1021/bi1009387. PubMed DOI PMC

Haendler B., Hofer‐Warbinek R., and Hofer E., “Complementary DNA for Human T‐Cell Cyclophilin,” EMBO Journal 6, no. 4 (1987): 947–950, 10.1002/j.1460-2075.1987.tb04843.x. PubMed DOI PMC

Zhou Z., Licklider L. J., Gygi S. P., and Reed R., “Comprehensive Proteomic Analysis of the Human Spliceosome,” Nature 419, no. 6903 (2002): 182–185, 10.1038/nature01031. PubMed DOI

Hegele A., Kamburov A., Grossmann A., et al., “Dynamic Protein‐Protein Interaction Wiring of the Human Spliceosome,” Molecular Cell 45, no. 4 (2012): 567–580, 10.1016/j.molcel.2011.12.034. PubMed DOI

Portela A. and Digard P., “The Influenza Virus Nucleoprotein: A Multifunctional RNA‐Binding Protein Pivotal to Virus Replication,” Journal of General Virology 83, no. 4 (2002): 723–734, 10.1099/0022-1317-83-4-723. PubMed DOI

Wang Z., Liu X., Zhao Z., et al., “Cyclophilin E Functions as a Negative Regulator to Influenza Virus Replication by Impairing the Formation of the Viral Ribonucleoprotein Complex,” PLoS One 6, no. 8 (2011): e22625, 10.1371/journal.pone.0022625. PubMed DOI PMC

Murti K. G., Webster R. G., and Jones I. M., “Localization of RNA Polymerases on Influenza Viral Ribonucleoproteins by Immunogold Labeling,” Virology 164, no. 2 (1988): 562–566, 10.1016/0042-6822(88)90574-0. PubMed DOI

Colwill K., Pawson T., Andrews B., et al., “The Clk/Sty Protein Kinase Phosphorylates SR Splicing Factors and Regulates Their Intranuclear Distribution,” EMBO Journal 15, no. 2 (1996): 265–275, 10.1002/j.1460-2075.1996.tb00357.x. PubMed DOI PMC

Nestel F. P., Colwill K., Harper S., Pawson T., and Anderson S. K., “RS Cyclophilins: Identification of an NK‐TR1‐Related Cyclophilin,” Gene 180, no. 1–2 (1996): 151–155, 10.1016/s0378-1119(96)00436-2. PubMed DOI

Stegmann C. M., Seeliger D., Sheldrick G. M., de Groot B. L., and Wahl M. C., “The Thermodynamic Influence of Trapped Water Molecules on a Protein‐Ligand Interaction,” Angewandte Chemie International Edition 48, no. 28 (2009): 5207–5210, 10.1002/anie.200900481. PubMed DOI

Bourquin J., “A Serine/Arginine‐Rich Nuclear Matrix Cyclophilin Interacts With the C‐Terminal Domain of RNA Polymerase II,” Nucleic Acids Research 25, no. 11 (1997): 2055–2061, 10.1093/nar/25.11.2055. PubMed DOI PMC

Agafonov D. E., Deckert J., Wolf E., et al., “Semiquantitative Proteomic Analysis of the Human Spliceosome via a Novel Two‐Dimensional Gel Electrophoresis Method,” Molecular and Cellular Biology 31, no. 13 (2011): 2667–2682, 10.1128/MCB.05266-11. PubMed DOI PMC

Cvitkovic I. and Jurica M. S., “Spliceosome Database: A Tool for Tracking Components of the Spliceosome,” Nucleic Acids Research 41, no. D1 (2013): D132–D141, 10.1093/nar/gks999. PubMed DOI PMC

Zhan X., Yan C., Zhang X., Lei J., and Shi Y., “Structure of a Human Catalytic Step I Spliceosome,” Science 359, no. 6375 (2018): 537–545, 10.1126/science.aar6401. PubMed DOI

Szlavicz E., Szabo K., Groma G., et al., “Splicing Factors Differentially Expressed in Psoriasis Alter MRNA Maturation of Disease‐Associated EDA+ Fibronectin,” Molecular and Cellular Biochemistry 436, no. 1–2 (2017): 189–199, 10.1007/s11010-017-3090-1. PubMed DOI

Zaba L. C., Suárez‐Fariñas M., Fuentes‐Duculan J., et al., “Effective Treatment of Psoriasis With Etanercept Is Linked to Suppression of IL‐17 Signaling, Not Immediate Response TNF Genes,” Journal of Allergy and Clinical Immunology 124, no. 5 (2009): 1022–1030, 10.1016/j.jaci.2009.08.046. PubMed DOI PMC

Hijnen D., Knol E. F., Gent Y. Y., et al., “CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN‐γ, IL‐13, IL‐17, and IL‐22,” Journal of Investigative Dermatology 133, no. 4 (2013): 973–979, 10.1038/jid.2012.456. PubMed DOI PMC

Teigelkamp S., Achsel T., Mundt C., et al., “The 20kD Protein of Human [U4/U6.U5] Tri‐SnRNPs Is a Novel Cyclophilin That Forms a Complex with the U4/U6‐Specific 60kD and 90kD Proteins.” RNA (New York, N.Y.) (1998). 4, 127–141. 2. PubMed PMC

Ingelfinger D., “Two Protein‐Protein Interaction Sites on the Spliceosome‐Associated Human Cyclophilin CypH,” Nucleic Acids Research 31, no. 16 (2003): 4791–4796, 10.1093/nar/gkg660. PubMed DOI PMC

Reidt U., Reuter K., Achsel T., Ingelfinger D., Lührmann R., and Ficner R., “Crystal Structure of the Human U4/U6 Small Nuclear Ribonucleoprotein Particle‐Specific SnuCyp‐20, a Nuclear Cyclophilin,” Journal of Biological Chemistry 275, no. 11 (2000): 7439–7442, 10.1074/jbc.275.11.7439. PubMed DOI

Horowitz D. S., Lee E. J., Mabon S. A., and Misteli T., “A Cyclophilin Functions in Pre‐MRNA Splicing,” EMBO Journal 21, no. 3 (2002): 470–480, 10.1093/emboj/21.3.470. PubMed DOI PMC

Rajiv C., Jackson S. R., Cocklin S., Eisenmesser E. Z., and Davis T. L., “The Spliceosomal Proteins PPIH and PRPF4 Exhibit Bi‐Partite Binding,” Biochemical Journal 474, no. 21 (2017): 3689–3704, 10.1042/BCJ20170366. PubMed DOI PMC

Adams B. M., Coates M. N., Jackson S. R., Jurica M. S., and Davis T. L., “Nuclear Cyclophilins Affect Spliceosome Assembly and Function PubMed DOI PMC

Li J., Zhou W., Wei J., et al., “Prognostic Value and Biological Functions of RNA Binding Proteins in Stomach Adenocarcinoma,” OncoTargets and Therapy 14 (2021): 1689–1705, 10.2147/OTT.S297973. PubMed DOI PMC

Gao L., Li G.‐S., Li J.‐D., et al., “Identification of the Susceptibility Genes for COVID‐19 in Lung Adenocarcinoma With Global Data and Biological Computation Methods,” Computational and Structural Biotechnology Journal 19 (2021): 6229–6239, 10.1016/j.csbj.2021.11.026. PubMed DOI PMC

Zhou Z., Ying K., Dai J., et al., “Molecular Cloning and Characterization of a Novel Peptidylprolyl Isomerase (Cyclophilin)‐Like Gene (PPIL3) From Human Fetal Brain,” Cytogenetic and Genome Research 92, no. 3–4 (2001): 231–236, 10.1159/000056909. PubMed DOI

Huang L.‐L., Zhao X.‐M., Huang C.‐Q., Yu L., and Xia Z.‐X., “Structure of Recombinant Human Cyclophilin J, a Novel Member of the Cyclophilin Family,” Acta Crystallographica. Section D: Biological Crystallography 61, no. 3 (2005): 316–321, 10.1107/S0907444904033189. PubMed DOI

Chen J., Chen S., Wang J., et al., “Cyclophilin J Is a Novel Peptidyl‐Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma,” PLoS One 10, no. 5 (2015): e0127668, 10.1371/journal.pone.0127668. PubMed DOI PMC

Gong Z., Mu Y., Chen J., et al., “Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma,” Anticancer Research 37, no. 8 (2017): 4475–4481, 10.21873/anticanres.11843. PubMed DOI

Huo D.‐H., Yi L.‐N., and Yang J., “Interaction With Ppil3 Leads to the Cytoplasmic Localization of Apoptin in Tumor Cells,” Biochemical and Biophysical Research Communications 372, no. 1 (2008): 14–18, 10.1016/j.bbrc.2008.04.178. PubMed DOI

Anderson S. K., Gallinger S., Roder J., Frey J., Young H. A., and Ortaldo J. R., “A Cyclophilin‐Related Protein Involved in the Function of Natural Killer Cells,” Proceedings of the National Academy of Sciences 90, no. 2 (1993): 542–546, 10.1073/pnas.90.2.542. PubMed DOI PMC

Rinfret A., Collins C., Menard R., and Anderson S. K., “The N‐Terminal Cyclophilin‐Homologous Domain of a 150‐Kilodalton Tumor Recognition Molecule Exhibits Both Peptidylprolyl Cis‐Trans‐Isomerase and Chaperone Activities,” Biochemistry 33, no. 7 (1994): 1668–1673, 10.1021/bi00173a008. PubMed DOI

Giardina S., Coffman J., Young H., et al., “Association of the Expression of an SR‐Cyclophilin With Myeloid Cell Differentiation,” Blood 87, no. 6 (1996): 2269–2274, 10.1182/blood.V87.6.2269.bloodjournal8762269. PubMed DOI

Zahler A. M., Neugebauer K. M., Lane W. S., and Roth M. B., “Distinct Functions of SR Proteins in Alternative Pre‐MRNA Splicing,” Science 260, no. 5105 (1993): 219–222, 10.1126/science.8385799. PubMed DOI

Li H. and Bingham P. M., “Arginine/Serine‐Rich Domains of the PubMed DOI

Frey J. L., Bino T., Kantor R. R., et al., “Mechanism of Target Cell Recognition by Natural Killer Cells: Characterization of a Novel Triggering Molecule Restricted to CD3‐Large Granular Lymphocytes,” Journal of Experimental Medicine 174, no. 6 (1991): 1527–1536, 10.1084/jem.174.6.1527. PubMed DOI PMC

Chambers C. A., Gallinger S., Anderson S. K., et al., “Expression of the NK‐TR Gene Is Required for NK‐Like Activity in Human T Cells,” Journal of Immunology 152, no. 6 (1994): 2669–2674, 10.4049/jimmunol.152.6.2669. PubMed DOI

Bai R., Shi Z., Li D., Zhou D., Ge W.‐T., and Zheng S., “Gene Expression Profile of Human Colorectal Cancer Identified NKTR as a Biomarker for Liver Metastasis,” Aging 14, no. 16 (2022): 6656–6667, 10.18632/aging.204242. PubMed DOI PMC

Ozaki K., Fujiwara T., Kawai A., et al., “Cloning, Expression and Chromosomal Mapping of a Novel Cyclophilin‐Related Gene (PPIL1) From Human Fetal Brain,” Cytogenetic and Genome Research 72, no. 2–3 (1996): 242–245, 10.1159/000134199. PubMed DOI

Xu C., Zhang J., Huang X., et al., “Solution Structure of Human Peptidyl Prolyl Isomerase‐Like Protein 1 and Insights into Its Interaction With SKIP,” Journal of Biological Chemistry 281, no. 23 (2006): 15900–15908, 10.1074/jbc.M511155200. PubMed DOI

Makarov E. M., Makarova O. V., Urlaub H., et al., “Small Nuclear Ribonucleoprotein Remodeling During Catalytic Activation of the Spliceosome,” Science 298, no. 5601 (2002): 2205–2208, 10.1126/science.1077783. PubMed DOI

Makarova O. V., Makarov E. M., Urlaub H., et al., “A Subset of Human 35S U5 Proteins, Including Prp19, Function Prior to Catalytic Step 1 of Splicing,” The EMBO Journal 23, no. 12 (2004): 2381–2391, 10.1038/sj.emboj.7600241. PubMed DOI PMC

Obama K., Kato T., Hasegawa S., Satoh S., Nakamura Y., and Furukawa Y., “Overexpression of Peptidyl‐Prolyl Isomerase‐Like 1 Is Associated With the Growth of Colon Cancer Cells,” Clinical Cancer Research 12, no. 1 (2006): 70–76, 10.1158/1078-0432.CCR-05-0588. PubMed DOI

Cassimeris L., “The Oncoprotein 18/Stathmin Family of Microtubule Destabilizers,” Current Opinion in Cell Biology 14, no. 1 (2002): 18–24, 10.1016/S0955-0674(01)00289-7. PubMed DOI

Wang B. B., Hayenga K. J., Payan D. G., and Fisher J. M., “Identification of a Nuclear‐Specific Cyclophilin Which Interacts With the Proteinase Inhibitor Eglin c,” Biochemical Journal 314, no. 1 (1996): 313–319, 10.1042/bj3140313. PubMed DOI PMC

Schiene‐Fischer C., “Multidomain Peptidyl Prolyl Cis/Trans Isomerases,” Biochimica et Biophysica Acta (BBA) ‐ General Subjects 1850, no. 10 (2015): 2005–2016, 10.1016/j.bbagen.2014.11.012. PubMed DOI

Hatakeyama S., Yada M., Matsumoto M., Ishida N., and Nakayama K.‐I., “U Box Proteins as a New Family of Ubiquitin‐Protein Ligases,” Journal of Biological Chemistry 276, no. 35 (2001): 33111–33120, 10.1074/jbc.M102755200. PubMed DOI

Hatakeyama S. and Nakayama K. I., “U‐Box Proteins as a New Family of Ubiquitin Ligases,” Biochemical and Biophysical Research Communications 302, no. 4 (2003): 635–645, 10.1016/S0006-291X(03)00245-6. PubMed DOI

Pushkarsky T., Yurchenko V., Vanpouille C., et al., “Cell Surface Expression of CD147/EMMPRIN Is Regulated by Cyclophilin 60,” Journal of Biological Chemistry 280, no. 30 (2005): 27866–27871, 10.1074/jbc.M503770200. PubMed DOI

Engdahl C., Näslund J., Lindgren L., Ahlm C., and Bucht G., “The Rift Valley Fever Virus Protein NSm and Putative Cellular Protein Interactions,” Virology Journal 9, no. 1 (2012): 139, 10.1186/1743-422X-9-139. PubMed DOI PMC

Qiu Z., Hao S., Song S., et al., “PLK1‐Mediated Phosphorylation of PPIL2 Regulates HR via CtiP,” Frontiers in Cell and Developmental Biology 10 (2022): 902403, 10.3389/fcell.2022.902403. PubMed DOI PMC

Madan S., Madan‐Khetarpal S., Park S. C., et al., “Left Ventricular Non‐Compaction on MRI in a Patient With 22q11.2 Distal Deletion,” American Journal of Medical Genetics, Part A 152A, no. 5 (2010): 1295–1299, 10.1002/ajmg.a.33367. PubMed DOI

Breckpot J., Thienpont B., Bauters M., et al., “Congenital Heart Defects in a Novel Recurrent 22q11.2 Deletion Harboring the Genes CRKL and MAPK1,” American Journal of Medical Genetics, Part A 158A, no. 3 (2012): 574–580, 10.1002/ajmg.a.35217. PubMed DOI

Zhang Y.‐H., Pan X., Zeng T., Chen L., Huang T., and Cai Y.‐D., “Identifying the RNA Signatures of Coronary Artery Disease From Combined LncRNA and MRNA Expression Profiles,” Genomics 112, no. 6 (2020): 4945–4958, 10.1016/j.ygeno.2020.09.016. PubMed DOI

Jia Z., Wang M., Li S., et al., “U‐Box Ubiquitin Ligase PPIL2 Suppresses Breast Cancer Invasion and Metastasis by Altering Cell Morphology and Promoting SNAI1 Ubiquitination and Degradation,” Cell Death & Disease 9, no. 2 (2018): 63, 10.1038/s41419-017-0094-4. PubMed DOI PMC

Espeseth A. S., Huang Q., Gates A., et al., “A Genome Wide Analysis of Ubiquitin Ligases in APP Processing Identifies a Novel Regulator of BACE1 MRNA Levels,” Molecular and Cellular Neuroscience 33, no. 3 (2006): 227–235, 10.1016/j.mcn.2006.07.003. PubMed DOI

Beyer N., Coulson D. T. R., Quinn J. G., et al., “MRNA Levels of BACE1 and Its Interacting Proteins, RTN3 and PPIL2, Correlate in Human Post Mortem Brain Tissue,” Neuroscience 274 (2014): 44–52, 10.1016/j.neuroscience.2014.05.020. PubMed DOI

Saigoh K., Wang Y.‐L., Suh J.‐G., et al., “Intragenic Deletion in the Gene Encoding Ubiquitin Carboxy‐Terminal Hydrolase in Gad Mice,” Nature Genetics 23, no. 1 (1999): 47–51, 10.1038/12647. PubMed DOI

Liu Y., Fallon L., Lashuel H. A., Liu Z., and Lansbury P. T., “The UCH‐L1 Gene Encodes Two Opposing Enzymatic Activities That Affect α‐Synuclein Degradation and Parkinson's Disease Susceptibility,” Cell 111, no. 2 (2002): 209–218, 10.1016/S0092-8674(02)01012-7. PubMed DOI

Ortolan T. G., Tongaonkar P., Lambertson D., Chen L., Schauber C., and Madura K., “The DNA Repair Protein Rad23 Is a Negative Regulator of Multi‐Ubiquitin Chain Assembly,” Nature Cell Biology 2, no. 9 (2000): 601–608, 10.1038/35023547. PubMed DOI

Zeng L., Zhou Z., Xu J., et al., “Molecular Cloning, Structure and Expression of a Novel Nuclear RNA‐Binding Cyclophilin‐Like Gene (PPIL4) From Human Fetal Brain,” Cytogenetic and Genome Research 95, no. 1–2 (2001): 43–47, 10.1159/000057015. PubMed DOI

Janowski B., Wöllner S., Schutkowski M., and Fischer G., “A Protease‐Free Assay for Peptidyl Prolyl Cis/Trans Isomerases Using Standard Peptide Substrates,” Analytical Biochemistry 252, no. 2 (1997): 299–307, 10.1006/abio.1997.2330. PubMed DOI

Jumper J., Evans R., Pritzel A., et al., “Highly Accurate Protein Structure Prediction With AlphaFold,” Nature 596, no. 7873 (2021): 583–589, 10.1038/s41586-021-03819-2. PubMed DOI PMC

Varadi M., Anyango S., Deshpande M., et al., “Alphafold Protein Structure Database: Massively Expanding the Structural Coverage of Protein‐Sequence Space With High‐Accuracy Models,” Nucleic Acids Research 50, no. D1 (2022): D439–D444, 10.1093/nar/gkab1061. PubMed DOI PMC

Kelley L. A., Mezulis S., Yates C. M., Wass M. N., and Sternberg M. J. E., “The Phyre2 Web Portal for Protein Modeling, Prediction and Analysis,” Nature Protocols 10, no. 6 (2015): 845–858, 10.1038/nprot.2015.053. PubMed DOI PMC

Deckert J., Hartmuth K., Boehringer D., et al., “Protein Composition and Electron Microscopy Structure of Affinity‐Purified Human Spliceosomal B Complexes Isolated under Physiological Conditions,” Molecular and Cellular Biology 26, no. 14 (2006): 5528–5543, 10.1128/MCB.00582-06. PubMed DOI PMC

Lin Y., Zhang M., Wang L., Pungpapong V., Fleet J. C., and Zhang D., “Simultaneous Genome‐Wide Association Studies of Anti‐Cyclic Citrullinated Peptide in Rheumatoid Arthritis Using Penalized Orthogonal‐Components Regression,” BMC Proceedings 3, no. S7 (2009): S20, 10.1186/1753-6561-3-S7-S20. PubMed DOI PMC

Barak T., Ristori E., Ercan‐Sencicek A. G., et al., “PPIL4 Is Essential for Brain Angiogenesis and Implicated in Intracranial Aneurysms in Humans,” Nature Medicine 27, no. 12 (2021): 2165–2175, 10.1038/s41591-021-01572-7. PubMed DOI PMC

BatemanBateman A., Martin M.‐J., Orchard S., et al., “UniProt: The Universal Protein Knowledgebase in 2023,” Nucleic Acids Research 51, no. D1 (2023): D523–D531, 10.1093/nar/gkac1052. PubMed DOI PMC

Mammalian Gene Collection (MGC) Program Team, “Generation and Initial Analysis of More Than 15,000 Full‐Length Human and Mouse CDNA Sequences,” Proceedings of the National Academy of Sciences 99, no. 26 (2002): 16899–16903, 10.1073/pnas.242603899. PubMed DOI PMC

Kelley L. A. and Sternberg M. J. E., “Protein Structure Prediction on the Web: A Case Study Using the Phyre Server,” Nature Protocols 4, no. 3 (2009): 363–371, 10.1038/nprot.2009.2. PubMed DOI

Nomura N., “Prediction of the Coding Sequences of Unidentified Human Genes. II. The Coding Sequences of 40 New Genes (KIAA0041‐KIAA0080) Deduced by Analysis of CDNA Clones From Human Cell Line KG‐1,” DNA Research 1, no. 5 (1994): 223–229, 10.1093/dnares/1.5.223. PubMed DOI

Jurica M. S. and Moore M. J., “Pre‐mRNA Splicing,” Molecular Cell 12, no. 1 (2003): 5–14, 10.1016/s1097-2765(03)00270-3. PubMed DOI

Xu C. and Min J., “Structure and Function of WD40 Domain Proteins,” Protein & Cell 2, no. 3 (2011): 202–214, 10.1007/s13238-011-1018-1. PubMed DOI PMC

Davis T. L., Walker J. R., Ouyang H., et al., “The Crystal Structure of Human WD40 Repeat‐Containing Peptidylprolyl Isomerase (PPWD1),” FEBS Journal 275, no. 9 (2008): 2283–2295, 10.1111/j.1742-4658.2008.06381.x. PubMed DOI

Stirnimann C. U., Petsalaki E., Russell R. B., and Müller C. W., “WD40 Proteins Propel Cellular Networks,” Trends in Biochemical Sciences 35, no. 10 (2010): 565–574, 10.1016/j.tibs.2010.04.003. PubMed DOI

Jeon J., Nim S., Teyra J., et al., “A Systematic Approach to Identify Novel Cancer Drug Targets Using Machine Learning, Inhibitor Design and High‐Throughput Screening,” Genome Medicine 6, no. 57 (2014): 57, 10.1186/s13073-014-0057-7. PubMed DOI PMC

Bertram K., El Ayoubi L., Dybkov O., et al., “Structural Insights into the Roles of Metazoan‐Specific Splicing Factors in the Human Step 1 Spliceosome,” Molecular Cell 80, no. 1 (2020): 127–139, 10.1016/j.molcel.2020.09.012. PubMed DOI

Posorski N., Kaemmerer D., Ernst G., et al., “Localization of Sporadic Neuroendocrine Tumors by Gene Expression Analysis of Their Metastases,” Clinical & Experimental Metastasis 28, no. 7 (2011): 637–647, 10.1007/s10585-011-9397-5. PubMed DOI

Kaemmerer D., Posorski N., von Eggeling F., et al., “The Search for the Primary Tumor in Metastasized Gastroenteropancreatic Neuroendocrine Neoplasm,” Clinical & Experimental Metastasis 31, no. 7 (2014): 817–827, 10.1007/s10585-014-9672-3. PubMed DOI

Mercer T. R., Dinger M. E., and Mattick J. S., “Long Non‐Coding RNAs: Insights Into Functions,” Nature Reviews Genetics 10, no. 3 (2009): 155–159, 10.1038/nrg2521. PubMed DOI

Sanchez Calle A., Kawamura Y., Yamamoto Y., Takeshita F., and Ochiya T., “Emerging Roles of Long Non‐Coding RNA in Cancer,” Cancer Science 109, no. 7 (2018): 2093–2100, 10.1111/cas.13642. PubMed DOI PMC

Sun H., Huang Z., Sheng W., and Xu M., “Emerging Roles of Long Non‐Coding RNAs in Tumor Metabolism,” Journal of Hematology & Oncology 11, no. 1 (2018): 106, 10.1186/s13045-018-0648-7. PubMed DOI PMC

Zeng Y., Wang K. X., Xu H., and Hong Y., “Integrative MiRNA Analysis Identifies Hsa‐miR‐3154, Hsa‐miR‐7‐3, and Hsa‐miR‐600 as Potential Prognostic Biomarker for Cervical Cancer,” Journal of Cellular Biochemistry 119, no. 2 (2018): 1558–1566, 10.1002/jcb.26315. PubMed DOI

Granados‐López A., Ruiz‐Carrillo J., Servín‐González L., et al., “Use of Mature MiRNA Strand Selection in MiRNAs Families in Cervical Cancer Development,” International Journal of Molecular Sciences 18, no. 2 (2017): 407, 10.3390/ijms18020407. PubMed DOI PMC

Han H.‐F., Chen Q., and Zhao W.‐W., “Long Non‐Coding RNA RP11‐284F21.9 Functions as a CeRNA Regulating PPWD1 by Competitively Binding to MiR‐769‐3p in Cervical Carcinoma,” Bioscience Reports 40, no. 9 (2020): BSR20200784, 10.1042/BSR20200784. PubMed DOI PMC

Paliouras A. R., Monteverde T., and Garofalo M., “Oncogene‐Induced Regulation of MicroRNA Expression: Implications for Cancer Initiation, Progression and Therapy,” Cancer Letters 421 (2018): 152–160, 10.1016/j.canlet.2018.02.029. PubMed DOI

Lin S. and Gregory R. I., “Microrna Biogenesis Pathways in Cancer,” Nature Reviews Cancer 15, no. 6 (2015): 321–333, 10.1038/nrc3932. PubMed DOI PMC

Li Y., Zhang H., Fan L., et al., “MiR‐629‐5p Promotes the Invasion of Lung Adenocarcinoma via Increasing Both Tumor Cell Invasion and Endothelial Cell Permeability,” Oncogene 39, no. 17 (2020): 3473–3488, 10.1038/s41388-020-1228-1. PubMed DOI

Qian G. F., Yuan L. S., Chen M., et al., “PPWD1 Is Associated With the Occurrence of Postmenopausal Osteoporosis as Determined by Weighted Gene Co‑Expression Network Analysis,” Molecular Medicine Reports 20, no. 4 (2019): 3202–3214, 10.3892/mmr.2019.10570. PubMed DOI PMC

Wu J., Matunis M. J., Kraemer D., Blobel G., and Coutavas E., “Nup358, a Cytoplasmically Exposed Nucleoporin With Peptide Repeats, Ran‐GTP Binding Sites, Zinc Fingers, a Cyclophilin A Homologous Domain, and a Leucine‐Rich Region,” Journal of Biological Chemistry 270, no. 23 (1995): 14209–14213, 10.1074/jbc.270.23.14209. PubMed DOI

Yokoyama N., Hayashi N., Seki T., et al., “A Giant Nucleopore Protein That Binds Ran/TC4,” Nature 376, no. 6536 (1995): 184–188, 10.1038/376184a0. PubMed DOI

Pichler A., Gast A., Seeler J. S., Dejean A., and Melchior F., “The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity,” Cell 108, no. 1 (2002): 109–120, 10.1016/S0092-8674(01)00633-X. PubMed DOI

Kassube S. A., Stuwe T., Lin D. H., et al., “Crystal Structure of the N‐Terminal Domain of Nup358/RanBP2,” Journal of Molecular Biology 423, no. 5 (2012): 752–765, 10.1016/j.jmb.2012.08.026. PubMed DOI PMC

Vetter I. R., Nowak C., Nishimoto T., Kuhlmann J., and Wittinghofer A., “Structure of a Ran‐Binding Domain Complexed With Ran Bound to a GTP Analogue: Implications for Nuclear Transport,” Nature 398, no. 6722 (1999): 39–46, 10.1038/17969. PubMed DOI

Reverter D. and Lima C. D., “Insights into E3 Ligase Activity Revealed by a SUMO–RanGAP1–Ubc9–Nup358 Complex,” Nature 435, no. 7042 (2005): 687–692, 10.1038/nature03588. PubMed DOI PMC

Geyer J. P., Döker R., Kremer W., Zhao X., Kuhlmann J., and Kalbitzer H. R., “Solution Structure of the Ran‐Binding Domain 2 of RanBP2 and Its Interaction With the C Terminus of Ran,” Journal of Molecular Biology 348, no. 3 (2005): 711–725, 10.1016/j.jmb.2005.02.033. PubMed DOI

Lin D. H., Zimmermann S., Stuwe T., Stuwe E., and Hoelz A., “Structural and Functional Analysis of the C‐Terminal Domain of Nup358/RanBP2,” Journal of Molecular Biology 425, no. 8 (2013): 1318–1329, 10.1016/j.jmb.2013.01.021. PubMed DOI PMC

Ferreira P. A., Yunfei C., Schick D., and Roepman R., “The Cyclophilin‐Like Domain Mediates the Association of Ran‐Binding Protein 2 With Subunits of the 19 S Regulatory Complex of the Proteasome,” Journal of Biological Chemistry 273, no. 38 (1998): 24676–24682, 10.1074/jbc.273.38.24676. PubMed DOI

Yi H., Friedman J. L., and A. Ferreira P., “The Cyclophilin‐Like Domain of Ran‐Binding Protein‐2 Modulates Selectively the Activity of the Ubiquitin‐Proteasome System and Protein Biogenesis,” Journal of Biological Chemistry 282, no. 48 (2007): 34770–34778, 10.1074/jbc.M706903200. PubMed DOI

Miklossy G., Hilliard T. S., and Turkson J., “Therapeutic Modulators of STAT Signalling for Human Diseases,” Nature Reviews Drug Discovery 12, no. 8 (2013): 611–629, 10.1038/nrd4088. PubMed DOI PMC

O'Shea J. J., Holland S. M., and Staudt L. M., “JAKs and STATs in Immunity, Immunodeficiency, and Cancer,” New England Journal of Medicine 368, no. 2 (2013): 161–170, 10.1056/NEJMra1202117. PubMed DOI PMC

Burda J. E. and Sofroniew M. V., “Reactive Gliosis and the Multicellular Response to CNS Damage and Disease,” Neuron 81, no. 2 (2014): 229–248, 10.1016/j.neuron.2013.12.034. PubMed DOI PMC

Kim H. J., Kim N. C., Wang Y.‐D., et al., “Mutations in Prion‐Like Domains in HnRNPA2B1 and HnRNPA1 Cause Multisystem Proteinopathy and ALS,” Nature 495, no. 7442 (2013): 467–473, 10.1038/nature11922. PubMed DOI PMC

Gardner J. C., Liew G., Quan Y.‐H., et al., “Three Different Cone Opsin Gene Array Mutational Mechanisms With Genotype‐Phenotype Correlation and Functional Investigation of Cone Opsin Variants,” Human Mutation 35 (2014): 1354–1362, 10.1002/humu.22679. PubMed DOI PMC

Cho K. I., Orry A., Park S. E., and Ferreira P. A., “Targeting the Cyclophilin Domain of Ran‐Binding Protein 2 (Ranbp2) With Novel Small Molecules to Control the Proteostasis of STAT3, HnRNPA2B1 and M‐Opsin,” ACS Chemical Neuroscience 6, no. 8 (2015): 1476–1485, 10.1021/acschemneuro.5b00134. PubMed DOI PMC

Ferreira P. A., Hom J. T., and Pak W. L., “Retina‐Specifically Expressed Novel Subtypes of Bovine Cyclophilin,” Journal of Biological Chemistry 270, no. 39 (1995): 23179–23188, 10.1074/jbc.270.39.23179. PubMed DOI

Ferreira P. A., Nakayama T. A., and Travis G. H., “Interconversion of Red Opsin Isoforms by the Cyclophilin‐Related Chaperone Protein Ran‐Binding Protein 2,” Proceedings of the National Academy of Sciences 94, no. 4 (1997): 1556–1561, 10.1073/pnas.94.4.1556. PubMed DOI PMC

Ferreira P. A., Nakayama T. A., Pak W. L., and Travis G. H., “Cyclophilin‐Related Protein RanBP2 Acts as Chaperone for Red/Green Opsin,” Nature 383, no. 6601 (1996): 637–640, 10.1038/383637a0. PubMed DOI

Singh B. B., Patel H. H., Roepman R., Schick D., and Ferreira P. A., “The Zinc Finger Cluster Domain of RanBP2 Is a Specific Docking Site for the Nuclear Export Factor, Exportin‐1,” Journal of Biological Chemistry 274, no. 52 (1999): 37370–37378, 10.1074/jbc.274.52.37370. PubMed DOI

Gareau J. R., Reverter D., and Lima C. D., “Determinants of Small Ubiquitin‐Like Modifier 1 (SUMO1) Protein Specificity, E3 Ligase, and SUMO‐RanGAP1 Binding Activities of Nucleoporin RanBP2,” Journal of Biological Chemistry 287, no. 7 (2012): 4740–4751, 10.1074/jbc.M111.321141. PubMed DOI PMC

Neilson D. E., Adams M. D., Orr C. M. D., et al., “Infection‐Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2,” American Journal of Human Genetics 84, no. 1 (2009): 44–51, 10.1016/j.ajhg.2008.12.009. PubMed DOI PMC

Sell K., Storch K., Hahn G., et al., “Variable Clinical Course in Acute Necrotizing Encephalopathy and Identification of a Novel RANBP2 Mutation,” Brain and Development 38, no. 8 (2016): 777–780, 10.1016/j.braindev.2016.02.007. PubMed DOI

Iyer G., Utage P., Bailur S., Utage A., Srirambhatla A., and Hasan Q., “Familial Acute Necrotizing Encephalopathy: Evidence From Next Generation Sequencing of Digenic Inheritance,” Journal of Child Neurology 35, no. 6 (2020): 393–397, 10.1177/0883073820902308. PubMed DOI

Jiang J., Wang Y. E., Palazzo A. F., and Shen Q., “Roles of Nucleoporin RanBP2/Nup358 in Acute Necrotizing Encephalopathy Type 1 (ANE1) and Viral Infection,” International Journal of Molecular Sciences 23, no. 7 (2022): 3548, 10.3390/ijms23073548. PubMed DOI PMC

Um J. W., Min D. S., Rhim H., Kim J., Paik S. R., and Chung K. C., “Parkin Ubiquitinates and Promotes the Degradation of RANBP2,” Journal of Biological Chemistry 281, no. 6 (2006): 3595–3603, 10.1074/jbc.M504994200. PubMed DOI

Hofemeister H. and O'Hare P., “Nuclear Pore Composition and Gating in Herpes Simplex Virus‐Infected Cells,” Journal of Virology 82, no. 17 (2008): 8392–8399, 10.1128/JVI.00951-08. PubMed DOI PMC

Carlon‐Andres I., Lagadec F., Pied N., et al., “Nup358 and Transportin 1 Cooperate in Adenoviral Genome Import,” Journal of Virology 94, no. 10 (2020): e00164‐20, 10.1128/JVI.00164-20. PubMed DOI PMC

Khuperkar D., Kamble A., Singh A., et al., “Selective Recruitment of Nucleoporins on Vaccinia Virus Factories and the Role of Nup358 in Viral Infection,” Virology 512 (2017): 151–160, 10.1016/j.virol.2017.09.012. PubMed DOI

Rosas‐Acosta G., Langereis M. A., Deyrieux A., and Wilson V. G., “Proteins of the PIAS Family Enhance the Sumoylation of the Papillomavirus E1 Protein,” Virology 331, no. 1 (2005): 190–203, 10.1016/j.virol.2004.10.025. PubMed DOI PMC

Lee J.‐G., Huang W., Lee H., van de Leemput J., Kane M. A., and Han Z., “Characterization of SARS‐CoV‐2 Proteins Reveals Orf6 Pathogenicity, Subcellular Localization, Host Interactions and Attenuation by Selinexor,” Cell & Bioscience 11, no. 1 (2021): 58, 10.1186/s13578-021-00568-7. PubMed DOI PMC

Ghildyal R., Jordan B., Li D., et al., “Rhinovirus 3C Protease Can Localize i the Nucleus and Alter Active and Passive Nucleocytoplasmic Transport,” Journal of Virology 83, no. 14 (2009): 7349–7352, 10.1128/JVI.01748-08. PubMed DOI PMC

Neufeldt C. J., Joyce M. A., Levin A., et al., “Hepatitis C Virus‐Induced Cytoplasmic Organelles Use the Nuclear Transport Machinery to Establish an Environment Conducive to Virus Replication,” PLoS Pathogens 9, no. 10 (2013): e1003744, 10.1371/journal.ppat.1003744. PubMed DOI PMC

Zhang L.‐K., Chai F., Li H.‐Y., Xiao G., and Guo L., “Identification of Host Proteins Involved in Japanese Encephalitis Virus Infection by Quantitative Proteomics Analysis,” Journal of Proteome Research 12, no. 6 (2013): 2666–2678, 10.1021/pr400011k. PubMed DOI

Schaller T., Ocwieja K. E., Rasaiyaah J., et al., “HIV‐1 Capsid‐Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency,” PLoS Pathogens 7, no. 12 (2011): e1002439, 10.1371/journal.ppat.1002439. PubMed DOI PMC

Hashizume C., Kobayashi A., and Wong R. W., “Down‐Modulation of Nucleoporin RanBP2/Nup358 Impaired Chromosomal Alignment and Induced Mitotic Catastrophe,” Cell Death & Disease 4, no. 10 (2013): e854, 10.1038/cddis.2013.370. PubMed DOI PMC

Ulrich A. and Wahl M. C., “Structure and Evolution of the Spliceosomal Peptidyl‐Prolyl PubMed DOI

Haselbach D., Komarov I., Agafonov D. E., et al., “Structure and Conformational Dynamics of the Human Spliceosomal Bact Complex,” Cell 172, no. 3 (2018): 454–464.e11, 10.1016/j.cell.2018.01.010. PubMed DOI

Zhang X., Yan C., Zhan X., Li L., Lei J., and Shi Y., “Structure of the Human Activated Spliceosome in Three Conformational States,” Cell Research 28, no. 3 (2018): 307–322, 10.1038/cr.2018.14. PubMed DOI PMC

Xu M., Xie Y., Abouzeid H., et al., “Mutations in the Spliceosome Component CWC27 Cause Retinal Degeneration With or Without Additional Developmental Anomalies,” American Journal of Human Genetics 100, no. 4 (2017): 592–604, 10.1016/j.ajhg.2017.02.008. PubMed DOI PMC

Cumberbatch M. G. K., Jubber I., Black P. C., et al., “Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018,” European Urology 74, no. 6 (2018): 784–795, 10.1016/j.eururo.2018.09.001. PubMed DOI

Aben K. K. H., Baglietto L., Baffoe‐Bonnie A., et al., “Segregation Analysis of Urothelial Cell Carcinoma,” European Journal of Cancer 42, no. 10 (2006): 1428–1433, 10.1016/j.ejca.2005.07.039. PubMed DOI

Wang M., Li Z., Chu H., et al., “Genome‐Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3,” Cancer Research 76, no. 11 (2016): 3277–3284, 10.1158/0008-5472.CAN-15-2564. PubMed DOI

Schiene‐Fischer C., Fischer G., and Braun M., “Non‐Immunosuppressive Cyclophilin Inhibitors,” Angewandte Chemie International Edition 61, no. 39 (2022): e202201597, 10.1002/anie.202201597. PubMed DOI PMC

Azzolin L., Antolini N., Calderan A., et al., “Antamanide, a Derivative of Amanita Phalloides, Is a Novel Inhibitor of the Mitochondrial Permeability Transition Pore,” PLoS One 6, no. 1 (2011): e16280, 10.1371/journal.pone.0016280. PubMed DOI PMC

Liddicoat A. M. and Lavelle E. C., “Modulation of Innate Immunity by Cyclosporine A,” Biochemical Pharmacology 163 (2019): 472–480, 10.1016/j.bcp.2019.03.022. PubMed DOI

Hopkins S. and Gallay P., “Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection,” Viruses 4, no. 11 (2012): 2558–2577, 10.3390/v4112558. PubMed DOI PMC

Czogalla A., “Oral Cyclosporine A—The Current Picture OF Its Liposomal and Other Delivery Systems,” Cellular and Molecular Biology Letters 14, no. 1 (2009): 139–152, 10.2478/s11658-008-0041-6. PubMed DOI PMC

Tapia C., Nessel T. A., and Zito P. M., Cyclosporine (Vol. 2023). StatPearls Publishing, 2023. PubMed

Stanciu C., Trifan A., Muzica C., and Sfarti C., “Efficacy and Safety of Alisporivir for the Treatment of Hepatitis C Infection,” Expert Opinion on Pharmacotherapy 20, no. 4 (2019): 379–384, 10.1080/14656566.2018.1560424. PubMed DOI

Gallay P. A., “Cyclophilin Inhibitors: A Novel Class of Promising Host‐Targeting Anti‐HCV Agents,” Immunologic Research 52 (2012): 200–210, 10.1007/s12026-011-8263-5. PubMed DOI PMC

Harrison S. A., Mayo P. R., Hobbs T. M., et al., “Rencofilstat, a Cyclophilin Inhibitor: A Phase 2a, Multicenter, Single‐Blind, Placebo‐Controlled Study in F2/F3 NASH,” Hepatology Communications 6, no. 12 (2022): 3379–3392, 10.1002/hep4.2100. PubMed DOI PMC

Malešević M., Kühling J., Erdmann F., et al., “A Cyclosporin Derivative Discriminates Between Extracellular and Intracellular Cyclophilins,” Angewandte Chemie International Edition 49 (2010): 213–215, 10.1002/anie.200904529. PubMed DOI PMC

Bobardt M., Hansson M. J., Mayo P., Ure D., Foster R., and Gallay P., “Structurally Distinct Cyclosporin and Sanglifehrin Analogs CRV431 and NV556 Suppress Established HCV Infection in Humanized‐Liver Mice,” PLoS One 15, no. 8 (2020): e0237236, 10.1371/journal.pone.0237236. PubMed DOI PMC

Simón Serrano S., Grönberg A., Longato L., et al., “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis,” Cells 8, no. 11 (2019): 1409, 10.3390/cells8111409. PubMed DOI PMC

Kuo J., Serrano S. S., Grönberg A., Massoumi R., Hansson M. J., and Gallay P., “Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non‐Alcoholic Steatohepatitis,” Frontiers in Pharmacology 10 (2019): 1129, 10.3389/fphar.2019.01129. PubMed DOI PMC

Tsuji A., Tamai I., Sakata A., Tenda Y., and Terasaki T., “Restricted Transport of Cyclosporin A Across the Blood‐Brain Barrier by a Multidrug Transporter, P‐Glycoprotein,” Biochemical Pharmacology 46, no. 6 (1993): 1096–1099, 10.1016/0006-2952(93)90677-O. PubMed DOI

Wang L., Wang N., Zhang W., et al., “Therapeutic Peptides: Current Applications and Future Directions,” Signal Transduction and Targeted Therapy 7, no. 48 (2022), 10.1038/s41392-022-00904-4. PubMed DOI PMC

Piotukh K., Gu W., Kofler M., Labudde D., Helms V., and Freund C., “Cyclophilin A Binds to Linear Peptide Motifs Containing a Consensus That Is Present in Many Human Proteins,” Journal of Biological Chemistry 280, no. 25 (2005): 23668–23674, 10.1074/jbc.M503405200. PubMed DOI

Reidt U., Wahl M. C., Fasshauer D., Horowitz D. S., Lührmann R., and Ficner R., “Crystal Structure of a Complex Between Human Spliceosomal Cyclophilin H and a U4/U6 SnRNP‐60K Peptide,” Journal of Molecular Biology 331, no. 1 (2003): 45–56, 10.1016/S0022-2836(03)00684-3. PubMed DOI

Daum S., Schumann M., Mathea S., et al., “Isoform‐Specific Inhibition of Cyclophilins,” Biochemistry 48, no. 26 (2009): 6268–6277, 10.1021/bi9007287. PubMed DOI PMC

Sambasivarao S. V. and Acevedo O., “Computational Insight into Small Molecule Inhibition of Cyclophilins,” Journal of Chemical Information and Modeling 51, no. 2 (2011): 475–482, 10.1021/ci1004114. PubMed DOI

Michel J., Simone A. D., Ioannidis C., et al., “Compounds for the Modulation of Cyclophilins Function.” WO2020043831A1, accessed March 5, 2020, https://patents.google.com/patent/WO2020043831A1/en?oq=wo2020%2f043831+a1.